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ABSTRACT OF THE DISSERTATION 
NOVEL INSIGHTS INTO THE MECHANISMS OF REGULATION OF TYROSINE 
KINASE RECEPTORS BY RAS INTERFERENCE 1 
by 
Adriana Galvis 
Florida International University, 2014 
Miami, Florida 
Professor Alejandro Barbieri, Major Professor 
Receptor-tyrosine kinases (RTKs) are membrane bound receptors 
characterized by their intrinsic kinase activity. RTK activities play an essential 
role in several human diseases, including cancer, diabetes and 
neurodegenerative diseases. RTK activities have been regulated by the 
expression or silencing of several genes as well as by the utilization of small 
molecules.  
Ras Interference 1 (Rin1) is a multifunctional protein that becomes 
associated with activated RTKs upon ligand stimulation. Rin1 plays a key role in 
receptor internalization and in signal transduction via activation of Rab5 and 
association with active form of Ras. This study has two main objectives: (1) It 
determines the role of Rin1 in the regulation of several RTKs focusing on insulin 
receptor. This was accomplished by studying the Rin1-insulin receptor interaction 
using a variety of biochemical and morphological assays. This study shows a 
novel interaction between the insulin receptor and Rin1 through the Vps9 
domain. Two more RTKs (epidermal growth factor receptor and nerve growth 
 vi
factor receptor) also interacted with the SH2 domain of Rin1. The effect of the 
Rin1-RTK interaction on the activation of both Rab5 and Ras was also studied 
during receptor internalization and intracellular signaling. Finally, the role of Rin1 
was examined in two differentiation processes (adipogenesis and neurogenesis). 
Rin1 showed a strong inhibitory effect on 3T3-L1 preadipocyte differentiation but 
it seems to show a modest effect in PC12 neurite outgrowth.  These data indicate 
a selective function and specific interaction of Rin1 toward RTKs. (2) It examines 
the role of the small molecule Dehydroleucodine (DhL) on several key signaling 
molecules during adipogenesis. This was accomplished by studying the 
differentiation of 3T3-L1 preadipocytes exposed to different concentrations of 
DhL in different days of the adipocyte formation process. The results indicate that 
DhL selectively blocked adipocyte formation, as well as the expression of 
PPARγ, and C/EBPα. However, DhL treatment did not affect Rin1 or Rab5 
expression and their activities.  
Taken together, the data indicate a potential molecular mechanism by 
which proteins or small molecules regulate selective and specific RTK 
intracellular membrane trafficking and signaling during cell growth and 
differentiation in normal and pathological conditions. 
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I. INTRODUCTION 
Endocytosis is the process by which cells internalize molecules from the 
extracellular environment (Besterman and Low, 1983). There are two different 
types depending on the size of the internalized particles. Phagocytosis refers to 
the invagination of particles larger than 250 nanometers, while pinocytosis refers 
to particles less than 100 nanometers (Besterman and Low, 1983). The second 
category can be further divided in to macropinocytosis and receptor-mediated 
endocytosis. The former requires actin cytoskeleton reorganization and provides 
a way to internalize, non-selectively, large quantities of solute molecules and 
membrane (Lim and Gleeson, 2011). Once inside the cell, these molecules are 
delivered into the lysosome, a compartment in which digestive enzymes break 
them down into metabolites that are released into the cytosol as they are needed 
for cell metabolism. Insulin (Maxfield et al., 1978) and growth factors such as 
brain-derived neurothropic factor (BDNF) (Patapoutian and Reichardt, 2001), 
fibroblast growth factor (FGF) (Ornitz and Itoh, 2001), platelet-derived growth 
factor (PDGF) (Hannink and Donoghue, 1989), insulin-like growth factor (IGF) 
(Hoppener et al., 1985), epidermal growth factor (EGF) (Harris et al., 2003), and 
nerve growth factor (NGF) (Alleva and Santucci, 2001) are examples of 
molecules that use this process for their internalization.   
Receptor Mediated Endocytosis 
Receptor-mediated endocytosis is initiated when a ligand binds to its 
receptor (Figure 1.1), which in turns initiates a series of protein-protein 
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interactions responsible for numerous cellular processes including cell 
proliferation, differentiation, growth, homeostasis, and apoptosis through the 
regulation of target genes. Receptor mediated endocytosis can be a constitutive 
or an activated process as in the case of transferrin (Goldstein et al., 1985) and 
EGF (Barbieri et al., 2003; Dunn and Hubbard, 1984; Schlessinger, 1981),  
respectively. 
Receptor-tyrosine kinases (RTKs) are internalized by receptor-mediated 
endocytosis. They are membrane-bound receptors characterized by their intrinsic 
kinase activity. They share a common structure characterized by 1) an 
extracellular region that interacts directly with the ligand; 2) a hydrophobic region 
that transverses the lipid bilayer; and 3) a cytoplasmic region that interacts with 
cytosolic molecules. Activated RTKs are responsible for multiple cellular 
processes including cell growth and apoptosis (Carpenter and Cantley, 1996; 
Riese and Stern, 1998; Zhou et al., 2000).  Examples of this type of receptor are 
fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor 
(PDGFR), insulin-like growth factor receptor (IGFR), the epidermal growth factor 
receptor (EGFR), insulin receptor (IR), and the nerve growth factor receptor 
(NGFR).  In general, the ligand binds to the extracellular domain of the receptor, 
triggering receptor dimerization, which in turn activates specific catalytic sites on 
the cytoplasmic face of the receptor, resulting in autophosphorylation of the 
receptor’s cytoplasmic tail and activation of multiple signal transduction cascades 
through protein-protein interactions (Hubbard and Miller, 2007). 
 3
Epidermal Growth Factor Receptor 
The EGFR belongs to a family composed of four types of receptors: 
ERBB1 (EGFR), ERBB2, ERBB3, and ERBB4. From these, ERBB2 does not 
bind any known EGF-like ligand; ERBB3 is kinase inactive, and ERBB4 is the 
only one autonomous (Bublil and Yarden, 2007). Upon ligand stimulation, ERBB4 
is the only one that does not have to form a dimer and that ERBB2 and ERBB3 
homodimers are not feasible because they lack ligand binding and kinase 
activity, respectively. As mentioned before, EGFR has the three different 
domains characteristic of RTKs: a ligand-binding extracellular domain, a 
hydrophobic transmembrane domain, and the tyrosine kinase activity cytoplasmic 
domain (Figure 1.2) (Carpenter, 1987; Downward et al., 1984; Hunter and 
Cooper, 1985). 
The EGFR family recognizes different types of ligands including EGF, 
Transforming Growth Factor-alpha (TGF-alpha), amphiregulin, betacellulin, 
epiregulin, and epigen (Nair, 2005). These receptors have a diffuse distribution 
on the cell surface when the ligand is not present. Upon EGF stimulation, the 
receptors cluster (homo or heteridimerization) in clathrin-coated pits to be 
internalized (Heath et al., 2003). Even though EGFR signaling is downregulated 
by the receptor internalization and targeting to the endosomal compartment 
(Holbro and Hynes, 2004), it is now known that it continues generating signals 
until its degradation in the lysosome (Avraham and Yarden, 2011).  At 
physiological levels of EGF (low doses 1-2 ng/ml), the receptor is internalized 
mainly through clathrin-coated pits (Sigismund et al., 2008). The process of 
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internalization is triggered by the direct interaction of the receptor tail with the 
adaptor protein AP2, which recruits clathrin to the plasma membrane creating the 
coated pit. The GTPase Dynamin is the one responsible for the vesicle fission 
from the plasma membrane forming the clathrin-coated vesicle (Schmid, 1997).  
Once inside the cell, the coat dissemble takes place, and the vesicle fuses with 
the early endosome continuing with the internalization process and the signaling 
cascade activated by the ligand-receptor complex (Kaksonen et al., 2006).   
Epidermal growth factor receptor signaling activates different types of 
transcription factors including c-jun, c-fos, c-myc, and NF-kB, (Holbro and Hynes, 
2004). Transcription factor regulation is done by the activation of key signaling 
pathways such as Erk and Akt, among others (Avraham and Yarden, 2011). 
Epidermal growth factor receptor signaling plays a key regulatory role in 
biological processes such as migration, proliferation, and resistance to apoptosis 
(Wieduwilt and Moasser, 2008). It is also a prominent regulator of cell lineage 
determination in different types of tissue (Figure 1.3). Overexpression of EGFR 
has been found in different types of cancer, specifically in breast and ovarian 
tumors (Nair, 2005). Recent studies have demonstrated the crosstalk between 
EGFR and GPCR (G-protein coupled receptors) and its importance in several 
cancers such as astrioglioma cells and ovarian cancer cells. The crosstalk 
between EGFR and GPCR is the result of EGFR activation by GPCR agonists 
(Gschwind et al., 2001). Aberrant EGFR activation through non-EGF may 
inactivate phosphatases that control the receptor intrinsic kinase activity, shifting 
the autophosphorylation/dephosphorylation equilibrium toward the active state 
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(Fischer et al., 2003).   Different key cytoplasmic proteins, such as Src and PKC, 
are involved depending on the system and the signaling context (Gschwind et al., 
2001). In summary, GPCR-induced activation of EGFR and downstream 
signaling through Src and PKC regulation are found in more than 60 human 
carcinoma cell lines derived from different tissues (Fischer et al., 2003).  
The Insulin Receptor 
The insulin receptor exists as a dimer composed of two α (extracellular) 
and two β (intracellular) subunits linked by a disulfide bond (Figure 1.4). There 
are two isoforms of the receptor that differ in 12 amino acids in the carboxyl 
terminus of the extracellular domain (the α-subunit). Some studies suggest that 
one isoform may signal more efficiently to metabolic processes while the other to 
mitogenic events (Belfiore et al., 2009). Despite the fact that both isoforms can 
form hetero- or homodimers to initiate the signaling cascade, they have higher 
affinity for only one ligand molecule upon stimulation (Siddle, 2011). As in the 
case of EGFR, the insulin receptor gets internalized through clathrin-coated pits 
and clathrin-coated vesicles until its fusion with early endosome, late endosome 
and finally the lysosome where its degradation takes place (Ceresa et al., 1998). 
Once the receptor gets activated upon insulin stimulation, it will initiate the 
signaling cascade as with other types of RTKs, with the exception of the insulin 
receptor substrate (IRS) protein recruitment. The activated receptor will recruit 
and phosphorylate IRS proteins, which are responsible for amplifying the signal 
by the recruitment and activation of SH2 domain-containing proteins (Su et al., 
2006). Ultimately these proteins will regulate the activity of several transcription 
 6
factors including TORC1 and FOXO through the PI3K/ Akt and GRB2-SOS/Ras 
cascades (Figure 1.5) (Cheng et al., 2010).  
Insulin signaling plays a major role in several biological processes 
including protein synthesis, lipid metabolism, glycolysis and glucose storage in 
muscle, liver and adipose tissue (Shaham et al., 2008). In muscle cells, insulin 
activates GLUT4 transporters from the cytoplasm to the plasma membrane 
increasing the intracellular concentration of glucose (Summers et al., 1998). In 
the liver, insulin stimulates glycogen synthesis by promoting the phosphorylation 
of glucose, confining it within the cell (Hua, 2010). In adipose tissue, insulin 
promotes the storage of lipids in the form of triglycerides by phosphorylating 
CREB protein and activating key adipogenic transcription factors such as PPARγ 
and C/EBPα as explained below.  Malfunction of these processes is associated 
with systemic disorders such as hypertension, obesity, diabetes, cardiovascular 
disease, infertility and neurodegeneration (Cheng et al., 2010; Reaven and Tsao, 
2003; Stumvoll et al., 2005). Recent studies demonstrated a crosstalk between 
insulin-like growth factor receptor (IGFR) and EGFR and its role in some types of 
hyper-proliferative diseases such as pancreatic and breast cancer (Ueda et al., 
2006). Insulin-like growth factor receptor, as well as the insulin receptor, is a 
member of the insulin-like growth factor receptor family. Both receptors have not 
only structural similarities, but also activate similar signaling cascades. It is 
believed the biological difference between the two receptors lies in its different 
tissue distribution and substrate recruitment (Werner et al., 2008). Depending on 
 7
the tissue and signaling context, it would not be unexpected to see a crosstalk 
not only between EGFR and IGFR but also with the insulin receptor. 
The Nerve Growth Factor Receptor  
The nerve growth factor receptor family is composed of the tropomyosin 
receptor kinase (Trk) and the p75 protein receptor (Sofroniew et al., 2001). There 
are three different Trk receptors, each composed of a single trans-membrane 
region and a cytosolic kinase domain (Figure 1.6). Tropomyosin receptor kinase 
A (TrkA) gets activated primarily by NGF, TrkB by BDNF, and neurotrophin 4/5 
and TrkC by neurotrophin 3. The Trk family of tyrosine kinase receptors regulates 
the development and maintenance of the peripheral and central nervous system 
(Brodeur et al., 2009).  This study will focus on TrkA. Tropomyosin receptor 
kinase A also uses the clathrin-mediated pathway for its internalization in the 
same way as EGFR and the insulin receptor (Grimes et al., 1996). The primary 
roles of NGF/TrkA signaling are to promote cell survival, neurite outgrowth, 
neuronal differentiation, and activity-dependent plasticity of sympathetic neurons 
(Brodeur et al., 2009). These biological processes are obtained by the activation 
of three major signaling pathways: PI3K/Akt, Erk, and Phospholipase C (PLC)/ 
protein kinase C (PKC), respectively (Figure 1.7).  Malfunction of these signaling 
pathways is related to various neurodegenerative diseases such as ALS 
(amyotrophic lateral sclerosis), Parkinson’s, Huntington’s and Alzheimer’s 
diseases as well as in different types of cancer including thyroid carcinoma and 
neuroblastoma (Brodeur et al., 2009; Connor and Dragunow, 1998; Kruttgen et 
al., 2006; Siegel and Chauhan, 2000).  
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Signal Transduction and Endocytosis 
Different proteins are involved in the signaling cascades activated by 
RTKs. After receptor activation, multiple proteins are recruited and play key roles 
in the activated signal cascade (Perona, 2006).  Studies have shown the 
important role the small GTPases Rab and Ras proteins play during receptor-
mediated endocytosis, membrane trafficking, vesicle transport, and signal 
transduction (Figure 1.8) (Agola et al., 2011; Hancock, 2003). These proteins 
cycle between their active form, bound to GTP, and their inactive form, bound to 
GDP.  Guanine nucleotide exchange factors (GEFs) promote the exchange from 
GDP to GTP, activating these small GTPases. On the other hand, GTPase 
activating proteins (GAPs) promote the hydrolization of GTP, inactivating them 
(Figure 1.9).   
Studies have shown the important regulatory role of Rab5 in the endocytic 
rate and early endosome fusion (Bucci et al., 1992; Li et al., 1994; Li and Stahl, 
1993; Roberts et al., 1999). As with other GTPases, Rab5 has a very low intrinsic 
GTPase activity, and depends on other enzymes such as GAPs to hydrolyze 
GTP, downregulating its activity. These enzymes share a common Tre-
2/Bub2/Cdc16 (TBC) catalytic domain responsible for GTP hydrolization.  
Examples of Rab5 GAP proteins are RabGap5, RN-tre (Pfeffer, 2005), and TBC-
2 (Chotard et al., 2010), among others (Figure 1.10). Multiple Rab5 GEFs have 
been identified. These proteins are characterized by sharing a highly conserved 
Vps9 (vacuolar protein sorting 9) domain that catalyzes the exchange from GDP 
to GTP, activating Rab5. Examples are the yeast homolog Vps9p (Hama et al., 
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1999), Rabex-5 (Carney et al., 2006), Rin1 (Han and Colicelli, 1995; Tall et al., 
2001), Alsin2 (Otomo et al., 2008), RME-6 (Sato et al., 2005), and Rap 6 (Hunker 
et al., 2006a; Sato et al., 2005) (Figure 1.11).  
Several of these proteins contain, besides the Vps9, other domains that 
interact and sequester other signaling molecules. Thus, their localization on early 
endosomes allows them to increase endocytosis by the activation of Rab5, and 
to regulate specific signaling cascades. The same is the case of Ras Interference 
1 (Rin1), which consists of four domains. First, the SH2 domain (SRC Homology 
2) located at the amino-terminus mediates a direct interaction with RTKs such as 
the IR and EGFR (Barbieri et al., 2003).  Second, the Proline Rich (PR) interacts 
with proteins such as the signal-transducing adaptor molecule (STAM) (Kong et 
al., 2007). Third, the Vps9 domain provides the site for the interaction and 
subsequent activation of Rab5, as explained above. Finally, the carboxy-terminus 
houses the Ras-Association (RA) domain, which interacts with the active form of 
Ras (Barbieri et al., 2003) (Figure 1.12). Ras Interference 1 competes with the 
Ras downstream effector Raf, inhibiting the its signaling cascade (Han and 
Colicelli, 1995). Thus, Rin1 is involved in both processes by its direct interaction 
through its three different domains with Rab5 (endocytosis) and Ras (cell 
signaling). Furthermore, it has been shown that several important residues of 
Rin1 play a key role in the activation of Rab5 (Galvis et al., 2009), and that it is 
potentiated by the interaction of Rin1 with the active form of Ras (Tall et al., 
2001).  
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Ras Interference 1 is part of a protein family composed of two other 
members: Rin2 and Rin3 (Figure 1.13). The former is also a Rab5-binding 
protein, but unlike Rin1, it has more affinity to Rab5-GTP; however, it also 
enhances the guanine nucleotide exchange activity of Rab5. Deficiency of Rin2 
has been related to a disorder of elastic tissue known as macrochepaly, alopecia, 
cutis laxa and scoliosis syndrome (MACS) (Basel-Vanagaite et al., 2009). Ras 
Interference 2 has the same domain structure as Rin1, with an extra proline rich 
domain. The same structure is observed in Rin3, except that it is composed of 
three proline rich domains.  It also binds the active form of Rab5 rather than the 
inactive one, just like Rin2 (Kajiho et al., 2003). It seems that Rin3 has a specific 
expression pattern restricted to mast cells, controlling basic functions as well as 
malfunction such as chronic inflammation and cell hyper proliferation (Janson et 
al., 2012).  
Hyperproliferative Diseases and Cancer  
Hyperproliferative diseases such as cancer are characterized by 
unregulated cell growth (Sebastian et al., 2006). Alterations in the equilibrium 
between cell proliferation and programmed cell death results in tumor formation 
as a consequence of uncontrolled cell division. Development and growth of 
cancer cells is produced by genetic modifications in signaling pathways that 
regulate cell proliferation, differentiation, survival and motility (Nicholson et al., 
2001). In most cases these signaling pathways are activated by RTKs, and their 
role in cancer development is, at least in part, a result of the receptor abnormal 
expression and activation. Aberrant EGFR (and its downstream signaling) 
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activation has been found in numerous types of cancer (Nair, 2005). The 
malfunction of EGFR has been supported by epidemiological evidence in human 
tumors, which demonstrated the contribution of abnormal EGFR expression and 
signaling in numerous epithelial malignancies including breast cancer (Suo and 
Nesland, 2002), squamous skin carcinomas (Merlino et al., 1985), renal 
carcinoma (Moch et al., 1997), head and neck tumors (Rogers et al., 2005), 
among others (Sebastian et al., 2006). The anomalous EGFR functioning 
includes activating mutations and receptor overexpression, which contributes to 
oncogenesis by inducing cell proliferation and apoptosis resistance (Henson and 
Gibson, 2006).   
Overactivated receptors such as EGFR and IGFR transform a normal cell 
to a malignant one by providing sustained signals that promote cell proliferation, 
anti-apoptosis, angiogenesis and metastasis, which are the basics properties of 
cancer development and progression (Arteaga, 2002). The GTPase Ras is a key 
regulator of signal transduction within the cell. It is a small GTPase that 
modulates signal activation upon membrane receptor stimulation. It has three 
isoforms: H-Ras, K-Ras, and N-Ras, all of which are involved in different types of 
tumors when over activated (Colicelli, 2004). The main deregulated signaling 
pathways involved in oncogenesis are the Raf-Erk, PI3K-Akt, and Jak-Stat (Nair, 
2005). The first one promotes cell proliferation and inhibits programmed cell 
death, by increasing the transcription of the BCL-2 family members and IAPs 
(inhibitor of apoptosis proteins) resulting in cell survival and proliferation (Henson 
and Gibson, 2006). The PI3K-Akt pathway also promotes cell survival and cell 
 12
growth through the activation of anti-apoptotic genes such as NFkB and CREB. 
Akt also phosphorylates the GSK3 kinase, inhibiting it, blocking transcriptional 
activity and metabolism regulation (Henson and Gibson, 2006).  Finally, the Jak-
Stat pathway promotes cell survival by the activation of survival genes through 
the translocation of Stat to the nucleus (Henson and Gibson, 2006).  
Malfunction of Rab5 has been related to different types of cancer. 
Upregulation of Rab5 expression has been associated with thyroid autonomous 
adenomas (Stein et al., 2003), and Rab5 activation has been shown to promote 
focal adhesion disassembly, enhancing migration and invasion of cancer cells 
(Mendoza et al., 2013).  Furthermore, Rin1 has also been related to multiple 
types of cancer. Rin1 localization has been shown to play an important role in 
colon cancer cells carcinogenesis (Inoue et al., 2011), while in breast cancer it 
seems to function as a tumor suppressor by negatively regulating tumor cell 
invasive growth (Milstein et al., 2007). On the other hand, on some non-small 
lung adenocarcinomas cell lines, upregulation of Rin1 expression seems to 
increase its proliferative properties (Tomshine et al., 2009). Taking these data 
together, it seems that the role of Rin1 in cancer progression is tissue-dependent 
and is related to the role of Rin1 as a Rab5 activator and a Ras effector.   
 Therefore, studying of the signaling pathways and its relationship with 
Rin1 is important to understand the molecular mechanisms of hyper proliferative 
diseases such as cancer.   
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Obesity and Diabetes  
  Obesity is a medical condition characterized by the excess accumulation 
of body fat. Fat deposits can be subcutaneous (beneath the skin) or visceral 
(around internal organs). The former is related to many of the obese-related 
pathologies such as cancer, heart disease and diabetes, among others (Hassan 
et al., 2012).   Diabetes is a metabolic disorder characterized by high blood 
glucose levels as a consequence of the inability of cells to absorb glucose. The 
high glucose levels happen because, at least in part, pancreatic beta cells are 
not able to produce insulin, or because cells cannot respond to the one produced 
properly, also known as insulin resistance (Guillausseau et al., 2008).  
Adipogenesis is the formation of adipocytes (fat cells) from preadipocytes 
(Rosen and Spiegelman, 2000). Different types of hormones and signaling 
cascades, including insulin, regulate this process (Figure 1.14). There are two 
main types of adipose tissue: white fat (WAT) and brown (BAT) tissue. White fat 
tissue stores excess energy in the form of triglycerides in large lipid droplets. 
White adipose tissue storage is important because by storing lipid excess, it 
prevents lipid accumulation in other tissues (Koppen and Kalkhoven, 2010). In 
addition, lipases hydrolyze triglycerides of WAT tissue into fatty acids that can be 
oxidized to generate energy as needed (Koppen and Kalkhoven, 2010; Rosen 
and Spiegelman, 2006). Recent studies have shown that WAT is not only the 
primary lipid storage, but that it also functions as an endocrine organ releasing 
different types of adipokines that regulate immune responses, blood pressure, 
angiogenesis, bone mass, thyroid and reproductive functions (Trayhurn, 2005). 
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On the other hand, BAT tissue is specialized in defense against cold and works 
as a protection against lipid accumulation by dissipating energy (instead of 
storing it) in the form of heat (Rosen and Spiegelman, 2000). This is achieved by 
an increase in the number of mitochondria present in this type of cell. 
Specifically, high expression of uncoupling protein (UCP)-1 dissipates the protein 
gradient across the inner mitochondrial membrane during the electron movement 
in the respiratory chain (Garlid et al., 1998). In BAT tissue, triglycerides are 
stored in multiple small lipid droplets (Cannon and Nedergaard, 2004). These two 
types of adipose tissue are found in multiple locations within the body. Usually 
they are found in areas rich in loose connective tissue (such as between muscle 
and dermis) and around major organs such as the heart and kidneys (Rosen and 
Spiegelman, 2000). White adipose tissue location has been associated with 
different types of diseases. Visceral adipose tissue is associated with an increase 
risk of cardiovascular malfunctions and insulin resistance, while subcutaneous 
tissue accumulation is not (Rosen and MacDougald, 2006).   
 Adipocyte differentiation occurs in two separate phases, each one marked 
and controlled by different transcription factors. The first phase is characterized 
by cell growth arrest followed by one or two rounds of mitosis known as clonal 
expansion. The second phase starts by a second round of growth arrest and is 
followed by the biochemical and morphological changes necessary to give rise to 
the adipocyte phenotype (Rosen and Spiegelman, 2000). The first factors to be 
activated during adipogenesis are the CCAAT/enhancer-binding proteins 
(C/EBP) β and γ (Evans et al., 2004). The early and transient activation of 
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C/EBPβ and γ is thought to be responsible for the clonal expansion, 
characteristic of the first phase, and for the induction of PPARγ and C/EBPα 
expression (Lane et al., 1999). Peroxisome proliferator-activated receptor γ is 
activated first and induces the expression of C/EBPα that at the same time, in a 
positive control, helps to maintain a high PPARγ expression level. These two 
transcription factors mediate the expression of adipocyte-specific genes that lead 
to the adipogenic differentiation phenotype (Hwang et al., 1997). The function of 
Erk activity is not clear yet. Some studies suggest a key role in the clonal 
expansion in the first phase of differentiation. Then it must be downregulated 
because Erk activity leads to phosphorylation of PPARγ, inhibiting adipocyte 
differentiation (Rosen and MacDougald, 2006) (Figure 1.15).  
 Malfunction in the equilibrium of adipose tissue can lead to numerous 
diseases including obesity, diabetes, insulin resistance, glucose intolerance, 
hypertension, nonalcoholic fatty liver and cardiovascular disease (Wang, 2010). 
Hence, it is necessary to study this biological process in detail as well as the 
proteins involved.   
Brain Function and Neurogenesis 
 Neurogenesis is the process by which new neurons are formed in the 
nervous system (Gotz and Huttner, 2005). Long branches that develop from the 
cell body characterize neuron cells. During neurogenesis, intracellular 
organization and assembly of microtubules and filamentous proteins of the 
cytoskeleton such as Maps (microtubule associated proteins) are involved in 
neurite growth (Biocca et al., 1983). Nerve growth factor is an essential 
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neurotrophin for cell differentiation and survival (Liu et al., 2007), it activates 
numerous signaling pathways by its binding to TrkA as explained above. Studies 
in PC (rat adrenal pheochromocytoma) 12 cells showed that the internalization of 
the TrkA/NGF complex and formation of the signaling endosome is essential for 
NFG-induced differentiation (Grimes et al., 1996). These signaling endosomes 
are involved in long distance retrograde transport in axons, compared with the 
short distance traveled by early endosomes in regular cells. Interestingly enough, 
a population of this neuronal signaling endosomes is also Rab5-positive (Liu et 
al., 2007). This suggests that Rab5 activity must be attenuated to prevent the 
transition to late endosomes and further degradation of the receptor complex 
terminating the signal. Low levels of Rab5-GTP found in differentiated PC12 cells 
suggest the NGF-induced signaling downregulation of Rab5 activity (Liu et al., 
2007).     
The ligand/receptor complex recruits proteins that activate the Ras and 
Rap1 GTPases, the ones that in turn activate Raf, PI3K, and PLC among other 
signaling proteins.  These are the main pathways responsible for the transcription 
of specific genes that commit to the differentiation process (Faigle and Song, 
2013; Wang et al., 2006).  
Neurodegenerative diseases such as Parkinson’s (Goedert, 2001), 
Alzheimer’s (Hardy and Selkoe, 2002), and Amyotrophic Lateral Sclerosis (ALS) 
(Qiang et al., 2013) are characterized by a loss in the neuronal population within 
the nervous system. The cell loss is responsible for the cognitive and motor 
function damage that comes as symptoms of such diseases (Abdipranoto et al., 
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2008).  Studies have shown neurogenesis in the adult nervous system (Eriksson 
et al., 1998), demonstrating the ability of some neuronal populations in the adult 
brain to regenerate themselves. These findings may suggest another approach 
to understand and cure neurodegenerative diseases: instead of focusing on 
slowing cell loss, the control and cure of these diseases can be in enhancing 
neurogenesis to replenish the neuronal population lost.  
Natural products: Phytochemicals 
The importance of natural products in medicine as well as in the 
agroindustry has led to numerous studies on the synthesis and biological 
activities of these substances. Yet little is now known about their actual roles in 
nature, particularly their use as alternative medicine. 
Many natural products show anti-obesity (Vasudeva et al., 2012) and anti-
tumoral activities of varying mechanisms (Aravindaram and Yang, 2010). 
Possibly a method to find a more efficient way to treat diseases like obesity and 
cancer, and more important, to achieve the synergistic effects of natural products 
should be to search for treatments using multiple products and/ or products 
having multiple biological activities. 
Sesquiterpene lactones are secondary metabolites found in most species 
of Compositae (Asteraceae), and there are more than 6,000 sesquiterpene 
lactones with known structures. Parthenolide was first reported as a new 
sesquiterpene lactone from Feverfew (Tanacetum parthenium) (Pareek et al., 
2011). Its organization revealed a structure of an alpha-methylene-gamma-
lactone. One of the most important characteristics of sesquiterpene lactones is 
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their anti-tumor activity (Zhang et al., 2005). Interestingly, a number of naturally 
occurring sesquiterpene lactones with the alpha-methylene-gamma-lactone 
(alpha-methylenenbutyrolactone) structure, such as parthenolide and helenalin, 
were reported to have potent cytotoxic activity toward several tumor cell lines as 
well as human cells transformed with Simian Virus (Lee et al., 1971; Wu et al., 
2006). Several studies have proposed that the anti-tumor activity of 
sesquiterpene lactones might occur at the DNA replication as well as other 
intracellular targets (Ross et al., 1999; Wiedhopf et al., 1973; Woynarowski and 
Konopa, 1981; Zhang et al., 2004). 
A sizeable body of written work indicates that exponential progress has 
been made concerning the knowledge of bioactive components in plant foods 
and their relation to obesity (Rayalam et al., 2008). Because adipogenesis is 
directly related to adipocyte differentiation and maturation, the induction of 
apoptosis as well as the inhibition of adipogenesis at various stages of the 
adipocyte life cycle may be target pathways for treating obesity.  
As described above, in cancer cells, phytochemicals have a propensity to 
increase the curative effect by either blocking one or more molecular targets of 
the signal transduction pathway of high proliferative cancer cells. However, 
dietary natural products have shown interesting effects on adipose tissue such as 
inducing apoptosis and decreasing lipid content (Nelson-Dooley et al., 2005), 
affecting a number of complex interconnected cell signaling pathways involved in 
regulating adipogenesis. Thus, natural compounds may act at single or multiple 
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target sites in the adipocyte or cancer cells life cycle associated with key 
physiological processes. 
About 25 percent of commonly used drugs to treat diseases such as 
diabetes, obesity and cancer come from plant extracts (Balandrin et al., 1985). 
Treatments to fight diseases such as obesity, and others illness related to it, 
focus on either to inhibit the formation or to promote apoptosis of adipose tissue. 
Plant extracts work on these two aspects with different mechanisms: to prevent 
the disease or to treat it.  Some plants extracts containing caffeine, are metabolic 
stimulants by inhibiting the degradation of intracellular cAMP that causes an 
increase in energy expenditure and decreases energy intake by reducing food 
intake (Dulloo, 1993; Racotta et al., 1994). Extract of Hoodia gordoni works as an 
appetite suppressant in rats, just as caffeine, by increasing ATP concentration in 
hypothalamic neurons that regulate food intake (MacLean and Luo, 2004).  
Studies showed the role of Siraitia grosvenori and Stachytarpheta 
cayennensis, among others, in insulin sensitivity and blood glucose control 
(Adebajo et al., 2007; Suzuki et al., 2007), even though the mechanism of 
regulation is not yet understood. Plants such as Cissus quadrangularis, Aralia 
mandshurica, Kochujang and psyllium showed a reduction in triglycerides and 
cholesterol levels in serum (Abidov et al., 2006; Ahn et al., 2006; Moreno et al., 
2003; Oben et al., 2007).  
Regulation of these signaling pathways, which can modulate adipogenesis 
at different developmental stages, is essential for several cellular processes. 
Several plant extracts have an effect on the first phase of differentiation. 
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Flavonoids (Hsu and Yen, 2006) and CLAs (Hsu and Yen, 2006) have been 
shown to inhibit 3T3-L1 preadipocyte proliferation and to induce apoptosis.  In 
the presence of genestein, mitotic clonal expansion of 3T3-L1 preadipocytes is 
inhibited (Harmon and Harp, 2001) and apoptosis of mature preadipocytes is 
enhanced in the presence of esculetin (Yang et al., 2006). Extracts such as 
EGCG, genistein and capsaicin were shown to activate AMPK, inhibiting phase 
two of adipogenic differentiation (Hwang et al., 2005).  
Natural products or their derivatives compose 67 percent of the anti-
cancer drug treatments (Balunas and Kinghorn, 2005; Ghantous et al., 2010). 
Plant metabolites containing sesquiterpene lactones have been studied as 
possible treatments for several human diseases, including inflammation, 
infections, headaches and cancer (Ghantous et al., 2010). Early work showed 
the importance of the biological activity of the α-methylene-γ-lactone structure in 
sesquiterpene lactones known to be cytotoxic to tumors (Hartwell and Abbott, 
1969). One of the benefits of the plant extract-based treatments in clinical trials is 
their ability to target tumor cells and cancer stem cells, without affecting normal 
healthy cells (Jordan, 2006; Kawasaki et al., 2009; Zhou and Zhang, 2008). The 
following are some examples of ongoing clinical trails based on plant extracts 
(Artemsia annua, Thapsia and Tanacetum parthenum, among others): laryngeal 
carcinomas, uveal melanomas, pituitary macrodenomas, lupus nephritis and 
breast, colorectal and nonsmall cell lung cancers (Berger et al., 2005; Lu, 2002; 
Singh and Panwar, 2006; Zhang et al., 2008). Even though the mechanism of 
action is still not fully understood, it seems that these plant extracts target the 
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sarco/ER calcium ATPase pump, proteases secreted by cancer cells, NF-kB 
signaling, p53 and transferrin receptor activity (Christensen et al., 2009; 
Denmeade and Isaacs, 2005; Efferth, 2006; Gopal et al., 2009; Hehner et al., 
1998; Nakase et al., 2009; Pajak et al., 2008). 
 
Hypothesis and Specific Aims 
As discussed above, receptor-mediated endocytosis initiates a series of 
protein-protein interactions responsible for essential cellular processes including 
cell proliferation, differentiation, and apoptosis through the regulation of selective 
and specific genes. Tyrosine kinase regulation changes gene modulation, which 
in turn affects whole-body metabolism involved in the pathogenesis of a variety of 
metabolic diseases, including Type 2 diabetes, cardiovascular disease, 
hypertension, stroke and some forms of cancer. 
The actual knowledge on receptor tyrosine kinases and small GTPases 
interaction is limited and holds high interest among cellular and molecular 
biologists. Specifically, how activation of receptor tyrosine kinases leads to 
upregulation of small GTPases, which orchestrate and regulate several signal 
transduction pathways, remains elusive and far from clear. Thus, the rationale for 
the dissertation is that the interaction between receptor tyrosine kinases, small 
molecules and regulators of small GTPases (these factors orchestrate and 
regulate intracellular membrane traffic, via intermediate multifunctional proteins) 
are most likely to be essential for modulation of several cellular events in normal 
and diseased cells. 
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The first part of this study addresses whether membrane targeting of Rin1 
by receptor tyrosine kinases plays a key role on the spatial and temporal 
regulation of Rab5 and Ras activities. Furthermore, it will examine how regulation 
of these small GTPases is connected to selective specific signaling pathways. 
Therefore, this part of the study will: 
1. Determine the mechanism of Rin1-RTKs interaction and its downstream effect 
in receptor internalization and activation of signaling cascades. 
2. Elucidate the role of Rin1 in different signaling pathways involved in cell 
differentiation. 
The second part of the dissertation focuses on anti-differentiation 
properties of a natural compound Dehydroleucodine (DhL) on in vitro 
adipogenesis using 3T3-L1 preadipocytes. As people become obese, their 
adipocytes enlarge and cause molecular and cellular alterations such as an 
increase in lipid accumulation and the deregulation of several signaling pathways 
involved in the pathogenesis of a variety of metabolic diseases. Hence, 
understanding the origin and development of adipocytes may be critical to the 
analysis and treatment of many chronic diseases. Therefore, this part of the 
study aims to: 
1. Determine the effect of DhL as a potent and selective inhibitor for 
adipogenesis. 
2. Elucidate the potential(s) mechanism(s) of action of DhL on adipogenesis. 
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This thesis is divided into five chapters: 
Chapter 1 is the introduction and literature review, which describes the 
importance of 1) RTK-membrane trafficking and signaling in normal and diseased 
cells and 2) natural products in biological processes.  
Chapter 2 examines the mechanism of interaction between Rin1 and RTKs and 
its regulation toward the activity on Rab5 and Ras in RTK internalization and 
signal transduction pathways, respectively. 
Chapter 3 focuses on the role of Rin1 (and Rin1-like molecules) in different 
signaling pathways involved in cell differentiation. 
Chapter 4 examines the effect of the small molecule Dehydroleucodine in 
differentiation of adipose cells. 
Chapter 5 summarizes the findings and significance of this research with future 
possibilities resulting from this study. 
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Figure 1.1. Receptor mediated endocytosis. 
Receptor mediated endocytosis is initiated when the ligand binds to the receptor 
at the plasma membrane originating a series of intracellular events, which will 
allow the formation of coated vesicles. The ligand-receptor complex is 
internalized in endocytic vesicles (early and late endosomes) that ultimately 
separate the complex degrading the ligand in the lysosomal compartment and 
recycling the receptor (in some cases) back to the cell surface. 
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Figure 1.2. EGFR structure. 
EGFR is composed in the extracellular (EC) region of two ligand-binding domains 
(LBD) and two cysteine-rich domains (CRD). The cytoplasmic tail, located inside 
the cell (IC), is composed of a tyrosine kinase domain (TKD) and a regulatory 
domain (RD). The extracellular and the cytoplasmic regions are divided by a 
transmembrane region (TMR). 
  
 26
 
Figure 1.3. EGFR signaling. 
Mayor signaling cascades activated by EGFR.  Once EGF binds to the receptor, 
Ras gets activated through the Grb2/SOS complex promoting the activation 
several signaling cascades including the Ral (Ras related protein)/PLD 
(phospholipase D), PI3K/ Akt, NORE1 (novel Ras effector 1)/MST (mammalian 
Sterile20-like), P190RhoGAP/ROCK (Rho-associated, coiled-coil containing 
protein kinase), PLC/Rap and Raf/Erk. 
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Figure 1.4. Insulin receptor structure. 
IR is composed of a ligand-binding domain in the extracellular region (EC) made 
up of two large leucine-rich domains (L1 and L2), a cysteine-rich domain (CR) 
and two fibronectin type domains (Fn0 and Fn1). The cytoplasmic tail is 
composed of a tyrosine kinase domain (TKD) and the carboxy-terminal tail (CT) 
located inside the cell (IC). The extracellular and the cytoplasmic regions are 
divided by a transmembrane region (TMR). 
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Figure 1.5. Insulin receptor signaling. 
Mayor signaling cascades activated by IR. Once insulin binds to the receptor, 
Ras gets activated through the Grb2/SOS complex promoting the activation 
several signaling cascades such as the phosphorylation of Erk.  
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Figure 1.6.  TrkA structure. 
TrkA is composed of a cysteine-rich (CR), a leucine-rich (L1) and a 
immunoglobin-like (Ig-like) domain in the extracellular region (EC). The 
cytoplasmic tail is composed of the tyrosine kinase domain (tyr 490, 674 and 
675) and the carboxy-terminal tail inside the cell (IC). The extracellular and the 
cytoplasmic regions are divided by a transmembrane region. 
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Figure 1.7. TrkA signaling. 
Mayor signaling cascades activated by TrkA. Once NGF binds to the receptor, 
two main pathways get activated: PI3K/Akt/BAD and Ras, promoting the 
activation several signaling cascades such as Mapk and BCL2.  
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Figure 1.8. Ras signaling. 
Mayor signaling cascades activated by Ras. Once the ligand binds to the 
receptor, Ras gets activated through the Grb2/SOS complex promoting the 
activation several signaling cascades including the Ral (Ras related protein)/PLD 
(phospholipase D), PI3K/ Akt, NORE1 (novel Ras effector 1)/MST (mammalian 
Sterile20-like), P190RhoGAP/ROCK (Rho-associated, coiled-coil containing 
protein kinase), PLC/Rap and Raf/Erk. Some Ras-GTP effectors compete for 
binding, such as Rin1 with PI3K and Raf.  
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Figure 1.9. Rab5/ Ras cycle. 
Rab5 and Ras GTPases cycle between its inactive form (bound to GDP) and its 
active form (bound to GTP). Guanine nucleotide exchange factors (GEFs) 
promote the GDP-GTP exchange, while GTPase activating proteins (GAPs) 
promote GTP hydrolysis. 
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Figure 1.10. Rab5 GAPs proteins. 
Proteins that promote GTP hydrolysis, inactivating Rab5. All of them share a 
TBC (Tre-2, Bub2 and Cdc16) domain responsible of the GTPase activity.  
RabGAP5 is composed of a TBC, SH3 (Src Homology 3) and RUN domains. 
TBC-2 is composed of PH (pleckstrin homology), CC (coiled coil), THR and TBC 
domains.  
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Figure 1.11. Rab5 GEFs proteins. 
Proteins that promote GDP-GTP exchange, activating Rab5. All of them share a 
Vps9 domain responsible for the Rab5 activation. Rin1 is composed of four 
domains. The N-terminus contains the SH2 (Src Homology 2) and PR (proline 
rich) domains. The Vps9 (vacuolar protein sorting 9) and the RA (Ras 
association) domains are located at the C-terminus. Rin1 variant lacks some 
amino acids on the Vps9 domain. Rin2 and Rin3 are composed of the same 
domains as Rin1, but they differ in the number of repeats of the PR domain.  
Alsin is composed of RL (RCC1-like domains), DH, PH (pleckstrin homology), 
MORN motifs and Vps9 domains.  Rabex-5 is composed of ZnF (Zinc finger), 
MIU (motif interacting with Ubiquitin), CC (coiled coil) and PR domains. Varp 
contains the Vps9a and two ankyrin domains. Rap6 is composed of Ras GAP, 
PH and Vps9 domains.  
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Figure 1.12. Rin1 domains. 
Rin1 is composed of four domains. The N-terminus contains the SH2 and PR 
domains. The Vps9 and the RA domains are located at the C-terminus. 
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Figure 1.13. Rin protein family. 
This protein family is composed of three members named Rin1, Rin2 and Rin3. 
All members are composed of the same domains: SH2, proline-rich (PR), Vps9 
and a RA domain. They differ in the number of repeats of the PR domain.   
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Figure 1.14. Adipogenesis signaling. 
Selective activation of key proteins on the different days of adipocyte 
differentiation. Adipogenesis is the result of specific activation of early (days 1 
and 2), intermediate (days 3 and 4) and late genes (days 5-9) as showed above.   
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Figure 1.15. Transcription factors involved in adipogenesis. 
Signaling cascades involved in fat cell formation. Insulin activate the IR and the 
Ras and PI3K signaling cascades. 1-Methyl-3-Isobutylxanthine (IBMX) activates 
C/EBPβ and dexamethasone (DEXA) is responsible for the activation of C/EBPδ. 
All together activate C/EBPα and PPARγ, the key adipogenic markers of 
adipogenesis.  
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II. MECHANISM OF INTERACTION BETWEEN RIN1 AND RTKS AND ITS 
EFFECTS TOWARD THE ACTIVITY OF RAB5 AND RAS. 
Tyrosine kinase receptors are membrane-bound receptors that get 
internalized through receptor-mediated endocytosis. These receptors share a 
common structure: an extracellular region responsible for the ligand interaction, a 
hydrophobic region that transverses the lipid bilayer, and a cytoplasmic tail that 
interacts with molecules inside the cell. Through the extracellular region, the 
receptor gets activated upon ligand binding. The ligand binding leads to 
autophosphorylation of the cytoplasmic tail of specific tyrosine residues, which 
then serve as docking sites for proteins containing an SH2 domain. The 
interaction between receptor cytoplasmic tail and SH2-containing proteins may 
represent one of the several mechanisms of the signal transduction regulation. 
Thus, the aim of this chapter is to determine key residues of Rin1 required for the 
interaction with tyrosine kinase receptors such as NGFR, EGFR, and IR and how 
this interaction affects several downstream signaling pathways. 
Interaction between Rin proteins and RTKs. 
Ras interference 1 interacts with activated EGFR through its SH2 domain 
(Barbieri et al., 2003). Key amino acids in this domain interact with the 
phosphorylated tyrosine residues in the cytoplasmic tail of the activated receptor.  
To study the interaction of Rin1 and EGFR two approaches were carried out: 
1- immunoprecipitation and 2- GST-pulldown. Each one of these assays is 
described in the Material and Methods section.  
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First, an immunoprecipitation assay was carried out by utilizing several Rin1 
constructs: Rin1:WT as well as individual Rin1 domains named Rin1:R2 (which 
contains SH2 and proline rich domains) and Rin1:R3 (which contains Vps9 and 
RA domains) (Figure 3.3).   
Second, a GST-pulldown was carried out by preparing cell lysates from 
stimulated (+EGF) and non-stimulated (-EGF) NR6 fibroblasts overexpressing 
EGFR, and the following GST-labeled purified proteins: Rin1 (SH2:WT), Rin1 
(SH2:H120L) and Rin1 (SH2:Y121F).  Glutathione S-transferase (GST) alone 
was used as negative control in these experiments. Figure 2.1 shows a specific 
interaction of EGFR with Rin1:WT and Rin1:R2 (Figure 2.1A,B), but not Rin1:R3 
(Figure 2.1 C). These results suggest that the SH2 domain of Rin1 recognizes 
phosphorylated tyrosine residues on the receptor cytoplasmic tail, which is 
present both in the Rin1:WT and Rin1:R2 constructs, but not in Rin1:R3.  
Previous studies showed the important role of arginine 94 (Rin1:R94A) of 
Rin1 in the interaction with EGFR (Hu et al., 2008). Figure 2.2 shows the 
interaction of EGFR and the GST-tagged Rin1:SH2 domain (WT and mutants). 
This time, two other point mutations were studied: Rin1:H120L and Rin1:Y121F. 
It can be observed that none of these mutants affected the Rin1/EGFR.  
To study the interaction of Rin1 and IR different techniques were utilized as 
described in the Material and Methods section. The same as with EGFR, an 
immunoprecipitation assay was used to study the Rin1-IR interaction. Figure 2.3 
shows that there is a specific interaction with the phosphorylated receptor 
(+insulin) with Rin1:WT (Figure 2.3A) and Rin1:R2 (Figure 2.3B) (which contains 
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the SH2 domain). Surprisingly, there is also a strong interaction with the Rin1:R3 
construct (Figure 2.3C). To further confirm this interaction, the yeast two hybrid 
method was used. Figure 2.4 shows the interaction between the IR tail and 
Rin1:R3. It also showed that Rin1:WT, as well as Rin1:R2, interact with the tail of 
the receptor as expected.  
Finally, a GST-pulldown assay was carried out using lysates from stimulated 
(+insulin) and non-stimulated (-insulin) NIH3T3 fibroblasts overexpressing IR, 
and the following GST-tagged purified proteins: Rin1 (SH2), Rin1 (SH2:W69E), 
Rin1 (SH2:A76E),  Rin1 (SH2:R94A), (SH2:H120L), (SH2:Y121F) and Rin1 
(SH2:Y148F).  Mutations in the SH2 domain of Rin1 were made on key amino 
acids that may play an important role in the interaction with RTKs. Figure 2.5A 
shows the Western blot and quantification of Rin1:WT, Rin1:W69A, and 
Rin1:A76E. Figure 2.5B shows the IR interaction with all mutants of the SH2 
domain of Rin1.  From the six mutants two of them have the most inhibitory effect  
(Rin1:A76E, Rin1:Y121F), while mutant Rin1:Y148F showed less inhibitory effect 
when compared to SH2:WT. Mutants W69E, R94A and Rin1:H120L have no 
effect at all in the interaction with the active IR.  
The Rin1-NGFR interaction was analyzed by doing a GST-pulldown assay 
(as described in the Material and Methods section) using cell lysates from 
stimulated (+NGF) and non-stimulated (-NGF) PC12 cells, which overexpress the 
TrkA receptor. Figure 2.6 shows a clear interaction of the receptor with Rin1 
upon NGF stimulation.  
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In summary, these results confirm that all three receptors interact with Rin1 
upon stimulation through the SH2 domain, which recognizes and binds to the 
phosphorylated tyrosines in the cytoplasmic tail of the activated receptor. 
Mutations on this domain have been related to different types of diseases such 
as leukemia (Cazzaniga et al., 1999), autoinflammatory disease (Zhou et al., 
2012), diabetes (Marion et al., 2002), and cancer (Friedman et al., 1993).  
Surprisingly, just the IR, and neither EGFR nor NGFR, interacts with the Vps9 
domain of Rin1. The Vps9 domain is responsible for the binding and further 
activation of Rab5 by promoting GDP to GTP exchange. 
Signaling regulation by Rin proteins. 
The next section describes 1- how these interactions affect the activity of key 
endocytic and signaling proteins such as Rab5 and Ras, respectively, and 2-  
how they affects major biological processes such as cell differentiation.  
Upon activation, RTKs initiate a cascade of protein-protein interactions that 
modulate the receptor internalization and signaling through the activation of the 
key GTPases Rab5 and Ras, respectively. Rab5 is responsible for the clathrin-
coated vesicle transportation from plasma membrane to early endosomes and its 
further homotypic early endosome docking and fusion (Barbieri et al., 1994; 
Bucci et al., 1992; Gorvel et al., 1991; Li et al., 1994; Zerial and McBride, 2001). 
Receptor activation promotes recruitment and activation of Rab5, as was 
demonstrated for EGFR (Barbieri et al., 2000). Rab5 is inactivated by the 
interaction with GAPs proteins, such as RabGap5 (Haas et al., 2005), RN-tre 
(Albert et al., 1999), and TBC-2 (Chotard et al., 2010), by promoting the 
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hydrolization of GTP into GDP. GEF proteins, such as Rabex5, Alsin2, Vps9p 
and Rin1, promote the exchange of GDP into GTP activating Rab5. All these 
proteins share a Vps9 domain, which is the one responsible for the activation 
(Carney et al., 2006).  
Figure 2.7 shows Rab5 activation in EGF-stimulated cells overexpressing Rin 
proteins. Ras interference 1 and Rin3 promote Rab5 activation compared with 
control, while Rin2 barely promoted any Rab5 activation (Figure 2.7). 
Interestingly, it was observed that all Rin family members also stimulated Rab5 
activity in non-stimulated cells (Figure 2.7). 
 In the case of IR, Rab5 activation shows a similar tendency as in EGF-
stimulated cells. (Figure 2.8) shows an increase in Rab5-GTP in Rin1 
overexpressing cells, and to a lesser extent, in cells overexpressing Rin2 and 
Rin3. Also observed was that overexpression of all Rin proteins stimulates Rab5 
activity in non-stimulated cells (Figure 2.8).  
Ras is a major signaling protein responsible of amplifying RTK signaling. 
Active Ras is important in cell differentiation and proliferation, and when it is 
overactive, it has been related to numerous types of cancer (Fernandez-Medarde 
and Santos, 2011). GTPase activating proteins (GAPs) and GEF proteins 
regulate Ras activity in the same way as Rab5, or any other GTPase protein. 
Ras activation is initiated by the activation of the receptor. Once the receptor is 
activated, an adaptor protein (GRB2) will bind through its SH2 domain to a 
phosphorylated tyrosine residue in the cytoplasmic tail of the receptor. GRB2 
also contains an SH3 domain, which will bind and activate SOS, a GEF, and 
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promote the GDP-GTP exchange activating Ras (Olivier et al., 1993). But Ras 
signaling regulation is much more complex than that. Proteins containing RA 
domain, such as Rin1, serve as Ras effectors (Ponting and Benjamin, 1996). 
These effectors directly interact with the active form of Ras, without having any 
effect on the rate of GTP hydrolysis. Even though Ras effectors do not inactivate 
Ras, they can have an impact in signaling cascades by competing with other 
effectors. This aim studied the effect of the Rin proteins in Ras and its signaling 
cascades activation.    
Figure 2.9 shows that there is no effect in Ras activity upon EGF 
stimulation if Rin1 is overexpressed when compared to control cells.  As 
mentioned above, Rin proteins have a domain (RA) that interacts with the active 
form of Ras (Barbieri et al., 2003). This interaction may have an effect in one or 
more signaling pathways activated by Ras.  
To study the effect of Rin overexpression in Ras-activated signal 
transduction several signaling proteins were examined. Figure 2.10 shows the 
effect of Rin1 overexpression in NR6 cells stimulated with EGF. As expected, the 
absence of EGF did not stimulate any of the activities analyzed (Figure 2.10A-E). 
A small inhibition of the tyrosine phosphorylation of EGFR was observed in cells 
expressing Rin1 (Figure 2.10E). Akt, Erk, and Junk activities were dramatically 
blocked in cells expressing Rin1 as compared with control-stimulated cells 
(Figure 2.10A,B and D). In contrast, p38 activity was not affected (Figure 2.10C). 
Rin2 overexpression in EGF-stimulated NR6 cells generated slightly different 
results. Figure 2.11 shows a significant inhibition of phosphorylated Akt (Figure 
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2.11B), while Erk (Figure 2.11A) activation seems to be enhanced. The activation 
of p38 (Figure 2.11C), similar to Rin1 overexpression, is not affected by the 
overexpression of Rin2. In the case of Rin3 overexpression, there is an inhibition 
in phosphorylated Erk (Figure 2.12A) and Akt (Figure 2.12B). Once again, there 
is no effect on p38 phosphorylation (Figure 2.12C), just as in the case of Rin1 
and Rin2 overexpression (Figure 2.12) upon EGF-stimulation. 
 The effect of Rin proteins overexpression was also studied in NIH3T3 
fibroblast overexpressing IR. Figure 2.13 shows the effect of Rin1 
overexpression in the Ras-activated signaling cascades. As in the EGFR 
overexpressed cells, Rin1 inhibits Erk (Figure 2.13A) and Akt (Figure 2.13B) 
phosphorylation upon insulin stimulation. In this case, opposite to what is 
observed upon EGF stimulation, Rin1 did not block p38 (Figure 2.13C) and IR 
(Figure 2.13D) phosphorylation upon stimulation. A similar tendency was 
observed when Rin2 is overexpressed. Figure 2.14 shows an inhibitory effect on 
Erk (Figure 2.14A) and Akt (Figure 2.14B) activation, while it promotes p38 
(Figure 2.14C) phosphorylation upon insulin stimulation. In the case of Rin3 
overexpression, Figure 2.15 shows a similar inhibitory effect on Erk (Figure 
2.15A) observed for Rin1 and Rin2, but this time there is no significant effect on 
Akt (Figure 2.15B) or p38 (Figure 2.15C) activation.  
To obtain a better understanding of the effect of Rin1 in IR signaling, 
several residues of each domain of Rin1 were mutated and their effects in insulin 
driven signaling pathways were studied. The following residues were mutated: 
Rin1:R94A (SH2 domain), Rin1:Y561F (Vps9 domain), Rin1:T580A (Vps9 
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domain) and Rin1:R629A (RA domain). Interestingly, arginine 94 is important in 
the interaction of Rin1 with activated EGFR (Hu et al., 2008).   Figure 2.16 shows 
that Rin1:R94A mutant has no effect on IR phosphorylation (Figure 2.16A), it 
reverses the inhibitory effect of Rin1:WT (Figure 2.16B), and more importantly, it 
has a greater inhibitory role than the wild type protein in Akt activation (Figure 
2.16C). It has been shown that tyrosine 561 is necessary for the proper activation 
of Rab5, and it is involved in the interaction with active Ras (Galvis et al., 2009). 
Figure 2.17 shows that Rin1:Y561F mutant has no effect in IR phosphorylation 
(Figure 2.17A), but it reverses the inhibitory effect caused by Rin1:WT in both Erk 
(Figure 2.17B) and Akt (Figure 2.17C) activity.  Figure 2.18 shows that 
Rin1:T580A mutant, which blocks Rab5 activation but not Ras binding (Galvis et 
al., 2009), enhances the phosphorylation of the receptor (Figure 2.18A) and 
reverses the inhibitory effect in both Erk (Figure 2.18B) and Akt (Figure 2.18C) 
phosphorylation.  Lastly, Rin1:R629A mutant, which affects the interaction with 
Ras, enhances the phosphorylation of IR (Figure 2.19A) and Akt (Figure 2.19C) 
compared to Rin1:WT, while it has a greater inhibitory effect on Erk (Figure 
2.19B) activity. Interestingly, all mutants promote the activation of p38 in non-
simulated cells; in some cases this activation is greater than the one observed in 
insulin stimulated cells (Figures 2.16- 2.19D). 
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Figure 2.1. Immunoprecipitation assay between Rin1 (WT and domains) and 
the EGF receptor.  
NR6 fibroblasts overexpressing EGFR, in the presence (+EGF) or absence (-
EGF) of 100ng/ul EGF, were lysed and immunoprecipitated as explained in 
Material and Methods. Stimulated and non-stimulated cell lysates were 
immunoprecipitated with a anti-EGFR antibody, and the presence of Rin1 (A), R2 
(B) or R3 (C) bound to the receptor was visualized using anti-Rin1 antibody. Rin1 
and EGFR present in the total cell lysate (TCL) shows the total amount of protein 
added to the assay. Rin1 present in the IP sample represents the amount of 
protein bound to the receptor. Relative levels of proteins were determined by 
densitometry as described in Material and Methods. Data represent the 
mean±S.E.M. of three independent experiments. *P<0.05 by Student's t-test 
compared to EGF-stimulated cells. 
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Figure 2.2. GST-pulldown assay between EGF receptor and Rin1 mutants.  
NR6 cells overexpressing EGFR, in the presence (+EGF) or absence (-EGF) of 
100ng/ul EGF, were lysed and incubated with GST-fused lysates of the different 
Rin1 constructs, as explained in Material and Methods. In the presence of EGF, 
cell lysates were incubated with Rin1:H120L and Rin1:Y121F mutants, and the 
amount of Rin1 protein bound to the receptor was visualized using anti-EGFR 
antibody. Relative levels of proteins were determined by densitometry as 
described in Material and Methods. Data represent the mean±S.E.M. of three 
independent experiments. *P<0.05 by Student's t-test compared to EGF-
stimulated cells.  
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Figure 2.3. Immunoprecipitation assay between Rin1 (WT and domains) and 
the insulin receptor.   
NIH3T3 fibroblasts overexpressing IR, in the presence (+Ins) or absence (-Ins) of 
100nM insulin, were lysed and immunoprecipitated as explained in Material and 
Methods.  Stimulated and non-stimulated cell lysates were immunoprecipitated 
with anti-IR antibody, and the presence of Rin1 (A), R2 (B) or R3 (C) bound to 
the receptor was visualized using anti-Rin1 antibody. Rin1 and IR present in the 
total cell lysate (TCL) shows the total amount of protein added to the assay. Rin1 
present in the IP sample represents the amount of protein bound to the receptor. 
Relative levels of proteins were determined by densitometry as described in 
Material and Methods. Data represent the mean±S.E.M. of three independent 
experiments. *P<0.05 by Student's t-test compared to insulin-stimulated cells. 
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Figure 2.4. Yeast two hybrid system using Rin1 constructs and the insulin 
receptor cytoplasmic tail.  
Rin1, R2 (SH2 and proline rich domains) and R3 (Vps9 and RA domains) were 
used to do the yeast two hybrid system with the insulin receptor cytoplasmic tail 
as explained in Materials and Methods. The insulin receptor tail: kinase dead was 
used as negative control. Data represent the mean±S.E.M. of three independent 
experiments. *P<0.05 by Student's t-test compared to IR: kinase dead (control). 
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Figure 2.5. GST-pulldown assay between the insulin receptor and Rin1 
mutants.  
Pure recombinant insulin receptor tail was phosphorylated in the presence of 
ATP, as explained in the Material and Methods section, prior to the binding to 
Rin1-SH2 mutants GST-fused lysates. The amount of Rin1 protein bound to the 
receptor was visualized using anti-IR antibody. (A) Western blot and 
quantification of the IR interaction with Rin1:SH2 WT, Rin1:W69A and Rin1: 
A76E. (B) Quantification of the IR interaction with the Rin1: SH2 mutants. 
Relative levels of proteins were determined by densitometry as described in 
Material and Methods. Data represent the mean±S.E.M. of three independent 
experiments. *P<0.05 by Student's t-test compared to Rin1:WT. 
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Figure 2.6. GST-pulldown assay between the NGF receptor and Rin1 
mutants.  
PC12 cells overexpressing TrkA, in the presence (+NGF) or absence (-NGF) of 
100nM NGF, were lysed and incubated with GST-tagged lysates of Rin1:SH2 
domain, as explained in Material and Methods. The amount of Rin1 protein 
bound to the receptor was visualized using anti-NGFR antibody. Relative levels 
of proteins were determined by densitometry as described in Material and 
Methods. Data represent the mean±S.E.M. of three independent experiments. 
*P<0.05 by Student's t-test compared to NGF-stimulated cells.  
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Figure 2.7. Rab5 activation in NR6 cells overexpressing EGFR and Rin 
proteins.  
Rab5 activation was measured as described in Materials and Methods in NR6 
control fibroblasts and cells overexpressing Rin1, Rin2 and Rin3 in the presence 
(+EGF) or absence (-EGF) of 100ng/μl EGF. Relative levels of proteins were 
determined by densitometry as described in Material and Methods. Data 
represent the mean±S.E.M. of three independent experiments. *P<0.05 by 
Student's t-test compared to EGF-stimulated cells. 
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Figure 2.8. Rab5 activation in NIH3T3 cells overexpressing Rin1.  
Rab5 activation was measured as described in Materials and Methods in NIH3T3 
control fibroblasts and cells overexpressing Rin1, Rin2 and Rin3 in the presence 
(+Ins) or absence (-Ins) of 100nM insulin. Relative levels of proteins were 
determined by densitometry as described in Material and Methods. Data 
represent the mean±S.E.M. of three independent experiments. *P<0.05 by 
Student's t-test compared to insulin-stimulated cells. 
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Figure 2.9. Ras activation in NR6 cells overexpressing Rin1. 
NR6 cells expressing GFP (circle-blue) and Rin1:WT (square-red)  were lysed 
and incubated with the GST-fused Ras binding domain of Raf . The pull-downs 
were subjected to SDS-PAGE and analyzed by Western blotting using an anti-
pan Ras antibody. Relative Units (% of maximum) of proteins were determined 
by densitometry using the ratio of active Ras to total-Ras. Data represent the 
mean±S.E.M. of three independent experiments. 
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Figure 2.10. EGFR signaling in NR6 cells overexpressing Rin1. 
NR6 fibroblasts control and cells overexpressing Rin1 were stimulated in the 
presence (+EGF) or absence (-EGF) of 100ng/μl EGF and the effect on 
phosphorylation of Erk (A), Akt (B), p38 (C), Junk (D), and EGFR (E) was 
measured on total cell lysates using the appropriate antibodies. Relative levels of 
proteins were determined by densitometry as described in Material and Methods. 
Data represent the mean±S.E.M. of three independent experiments. *P<0.05 by 
Student's t-test compared to EGF-stimulated cells. **P<0.05 by Student's t-test 
compared to Rin1 overexpressing/ EGF-stimulated cells. 
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Figure 2.11. EGFR signaling in NR6 cells overexpressing Rin2. 
NR6 fibroblasts control and cells overexpressing Rin2 were stimulated in the 
presence (+EGF) or absence (-EGF) of 100ng/μl EGF and the effect on 
phosphorylation of Erk (A), Akt (B) and p38 (C), was measured on total cell 
lysates using the appropriate antibodies. Relative levels of proteins were 
determined by densitometry as described in Material and Methods. Data 
represent the mean±S.E.M. of three independent experiments. *P<0.05 by 
Student's t-test compared to EGF-stimulated cells. **P<0.05 by Student's t-test 
compared to Rin2 overexpressing/ EGF-stimulated cells. 
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Figure 2.12. EGFR signaling in NR6 cells overexpressing Rin3. 
NR6 fibroblasts control and cells overexpressing Rin3 were in the presence 
(+EGF) or absence (-EGF) of 100ng/μl EGF and the effect on phosphorylation of 
Erk (A), Akt (B) and p38 (C), was measured on total cell lysates using the 
appropriate antibodies. Relative levels of proteins were determined by 
densitometry as described in Material and Methods. Data represent the 
mean±S.E.M. of three independent experiments. *P<0.05 by Student's t-test 
compared to EGF-stimulated cells. **P<0.05 by Student's t-test compared to 
Rin3 overexpressing/ EGF-stimulated cells. 
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Figure 2.13. IR signaling in NIH3T3 cells overexpressing Rin1. 
NIH3T3 fibroblasts control and cells overexpressing Rin1 were stimulated in the 
presence (+Ins) or absence (-Ins) of 100nM insulin and the effect on 
phosphorylation of Erk (A), Akt (B), p38 (C), and IR (D) was measured on total 
cell lysates using the appropriate antibodies. Relative levels of proteins were 
determined by densitometry as described in Material and Methods. Data 
represent the mean±S.E.M. of three independent experiments. *P<0.05 by 
Student's t-test compared to insulin-stimulated cells. **P<0.05 by Student's t-test 
compared to Rin1 overexpressing/ EGF-stimulated cells. 
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Figure 2.14. IR signaling in NIH3T3 cells overexpressing Rin2. 
NIH3T3 fibroblasts control and cells overexpressing Rin2 were stimulated in the 
presence (+Ins) or absence (-Ins) of 100nM insulin and the effect on 
phosphorylation of Erk (A), Akt (B), and p38 (C) was measured on total cell 
lysates using the appropriate antibodies. Relative levels of proteins were 
determined by densitometry as described in Material and Methods. Data 
represent the mean±S.E.M. of three independent experiments. *P<0.05 by 
Student's t-test compared to insulin-stimulated cells. **P<0.05 by Student's t-test 
compared to Rin2 overexpressing/ EGF-stimulated cells. 
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Figure 2.15. IR signaling in NIH3T3 cells overexpressing Rin3. 
NIH3T3 fibroblasts control and cells overexpressing Rin3 were stimulated in the 
presence (+Ins) or absence (-Ins) of 100nM insulin and the effect on 
phosphorylation of Erk (A), Akt (B), and p38 (C) was measured on total cell 
lysates using the appropriate antibodies. Relative levels of proteins were 
determined by densitometry as described in Material and Methods. Data 
represent the mean±S.E.M. of three independent experiments. *P<0.05 by 
Student's t-test compared to insulin-stimulated cells. **P<0.05 by Student's t-test 
compared to Rin3 overexpressing/ EGF-stimulated cells. 
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Figure 2.16. IR signaling in NIH3T3 cells overexpressing Rin1:R94A mutant.  
NIH3T3 fibroblasts overexpressing Rin1:WT (used as control) and Rin1:R94A 
were stimulated in the presence (+Ins) or absence (-Ins) of 100nM insulin and the 
effect on phosphorylation of IR (A) Erk (B), Akt (C), and p38 (D) was measured 
on total cell lysates using the appropriate antibodies. Relative levels of proteins 
were determined by densitometry as described in Material and Methods. Data 
represent the mean±S.E.M. of three independent experiments. *P<0.05 by 
Student's t-test compared to insulin-stimulated cells. **P<0.05 by Student's t-test 
compared to Rin1:WT overexpressing/ EGF-stimulated cells. 
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Figure 2.17. IR signaling in NIH3T3 cells overexpressing Rin1: Y561F 
mutant.  
NIH3T3 fibroblasts overexpressing Rin1:WT (used as control) and Rin1:Y561F 
were stimulated in the presence (+Ins) or absence (-Ins) of 100nM insulin and the 
effect on phosphorylation of IR (A) Erk (B), Akt (C), and p38 (D) was measured 
on total cell lysates using the appropriate antibodies. Relative levels of proteins 
were determined by densitometry as described in Material and Methods. Data 
represent the mean±S.E.M. of three independent experiments. *P<0.05 by 
Student's t-test compared to insulin-stimulated cells. **P<0.05 by Student's t-test 
compared to Rin:WT overexpressing/ EGF-stimulated cells. 
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Figure 2.18. IR signaling in NIH3T3 cells overexpressing Rin1: T580A 
mutant.  
NIH3T3 fibroblasts overexpressing Rin1:WT (used as control)  and Rin1:T580A 
were stimulated in the presence (+Ins) or absence (-Ins) of 100nM insulin and the 
effect on phosphorylation of IR (A) Erk (B), Akt (C), and p38 (D) was measured 
on total cell lysates using the appropriate antibodies. Relative levels of proteins 
were determined by densitometry as described in Material and Methods. Data 
represent the mean±S.E.M. of three independent experiments. *P<0.05 by 
Student's t-test compared to insulin-stimulated cells. **P<0.05 by Student's t-test 
compared to Rin1:WT overexpressing/ EGF-stimulated cells. 
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Figure 2.19. IR signaling in NIH3T3 cells overexpressing Rin1:R629A 
mutant.  
NIH3T3 fibroblasts overexpressing Rin1:WT (used as control) and Rin1:R629A 
were stimulated in the presence (+Ins) or absence (-Ins) of 100nM insulin and the 
effect on phosphorylation of IR (A) Erk (B), Akt (C), and p38 (D) was measured 
on total cell lysates using the appropriate antibodies. Relative levels of proteins 
were determined by densitometry as described in Material and Methods. Data 
represent the mean±S.E.M. of three independent experiments. *P<0.05 by 
Student's t-test compared to insulin-stimulated cells. **P<0.05 by Student's t-test 
compared to Rin1:WT overexpressing/ EGF-stimulated cells. 
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III. THE ROLE OF RIN1 (AND RIN1-LIKE MOLECULES) IN SIGNALING 
TRANSDUCTION PATHWAYS INVOLVED IN CELL DIFFERENTIATION.  
Cell proliferation, differentiation, and apoptosis are exceptionally similar 
processes in both normal and diseased cells. However, they show unique traits. 
Cell proliferation is a complex molecular mechanism that involves the regulation 
of genes. These genes are required for cell division cycle, which is an orderly 
and unidirectional transition from one cell cycle phase to the next. Cell 
differentiation is a process in which a cell develops into certain type upon specific 
stimulation. Cell differentiation changes a cell's size, shape, intracellular 
metabolism, and more important it is sensitive to external signals. These 
changes are largely the result of highly controlled and regulated gene expression 
upon stimulation. Several in vitro differentiation systems have been described. 
Here, two in vitro differentiation systems, 3T3L1 preadipocytes and PC12 cells, 
are studied. 
Adipogenesis is the formation of adipocytes (fat cells) from preadipocytes. 
Different types of hormones and signaling cascades, including insulin, regulate 
this process. To study adipogenesis in vitro, preadipocytes cells are exposed to 
an induction cocktail composed of insulin, dexamethasone (dexa) and 1-Methyl-
3-Isobutylxanthine (IBMX). The induction cocktail actives adipogenic factors 
C/EPBβ and δ, which are responsible for the activation of C/EBPα and PPARγ. 
The last ones are key regulators of adipogenesis; they are responsible for the 
morphological and transcriptional changes in adipocytes. Ras interference 1, as 
explained above, is a multifunctional protein involved both in the internalization 
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and signal transduction of IR. In the present study 3T3-L1 preadipocytes cells 
were used to determine the effects of Rin1 (its domains and Rin1-like molecules) 
during the differentiation process. Several Rin1 point mutations as well as Rin1 
deletion mutants were created on key amino acids that affect the function of each 
domain in order to analyze their effects on preadipocyte differentiation in vitro.  
Ras interference 1 is part of a protein family composed of two other 
members: Rin2 and Rin3. The three of them share a highly conserved Vps9 
domain that activates Rab5. Figure 3.1 shows the endogenous expression levels 
of Rab5 and Rin1 in days 1, 3, 5 and 10 of differentiation. The expression of 
Rab5 increases until day 5, and then there is a decrease up to day 10 (Figure 
3.1A). In the case of Rin1, it highly expressed in fibroblasts, and upon 
stimulation, there is a constant decrease (Figure 3.1B). To study the effect of Rin 
proteins in 3T3-L1 differentiation, stable cell lines were done, differentiated for 
ten days and the lipid droplet formation quantified as explained in Materials and 
Methods. Figure 3.2A shows that individual overexpression of Rin proteins 
inhibited adipocyte differentiation. Ras interference 1 showed the greater 
inhibitory effect. In contrast, when Rin1 is depleted by RNAi, the inhibitory effect 
was not observed (Figure 3.2B). 
To determine which specific domain of Rin1 is responsible for the 
inhibitory effect on adipocyte differentiation, the N- (Rin1:R2), C-terminus 
(Rin1:R3) and each individual domain were cloned and overexpressed in 3T3-L1 
cells (Figure 3.3). Following the protocol described in Material and Methods 
section, the lipid droplet formation was quantified at day 10 of differentiation and 
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is showed in Figure 3.2C. As expected, the C-terminus (Rin1:R3) and the Vps9 
domain alone (Rin1:R4) were enough to produce the inhibitory effect. 
Surprisingly, the same was observed for each individual domain (SH2 and RA) 
and for the N-terminus. All of them had a similar inhibitory effect as Rin1:WT.  
 To confirm the morphological effects and lipid quantification, expression of 
key adipogenic markers (C/EBPα and PPARγ) and signaling proteins (Erk and 
Akt) were studied on day 10 of differentiation of all cell lines overexpressing Rin1 
and its domains. Figure 3.4 shows that the expression of both C/EBPα (Figure 
3.4A) and PPARγ (Figure 3.4B) is inhibited compared to control cells, supporting 
the morphological and lipid quantification data.  The expression of PPARγ is 
dramatically inhibited, which explains why the cells overexpressing Rin1 
resemble a fibroblast-like shape instead of an adipocyte one. PPARγ is known to 
be the master regulator of adipocyte differentiation; its expression in the cell is 
absolutely necessary in order for adipogenesis to occur. On the other hand, 
activation of important signaling proteins such as Erk (Figure 3.4C) and Akt 
(Figure 3.4D), does not seem to be affected by the overexpression of Rin1. 
These observations may suggest that the mechanism used by Rin1 to inhibit 
adipogenesis is independent from the Erk and PI3K signaling pathways. Figure 
3.5 shows that the different Rin1 domains have the same inhibitory tendency on 
the adipogenic markers as Rin1:WT. Again, PPARγ (Figure 3.5B) is the one 
inhibited the most, even though the higher inhibition is observed by the 
expression of Rin1:WT, but not by the expression of any specific Rin1 domain. 
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 In an effort to elucidate which Rin1 domain(s) is/are required in the 
inhibition of differentiation, the following key amino acids (for the proper 
functioning) of the SH2, Vps9 and RA domains were mutated and overexpressed 
as described in Material and Methods section:  Rin1:R94A, Rin1:Y561F, 
Rin1:R94A+Y561F, Rin1:T580A and Rin1:R629A. Each mutant is able to reverse 
the inhibitory effect shown by its domain, as it is shown in Figure 3.6. The same 
is observed in the expression of the key adipogenic markers: the Rin1 mutants 
are almost able to restore the normal expression levels for C/EBPα and PPARγ 
(Figure 3.7A and B, respectively).  The effect of the Rin1 mutants supports 
previous morphological and biochemical data that show that all the domains play 
an important role in the inhibitory effect that Rin1 has in adipocyte differentiation 
(Figure 3.3).   
In order to understand the molecular mechanism by which Rin1 inhibits in 
vitro differentiation of 3T3-L1 cells, controls as well as Rin1-overexpressing cells 
were differentiated and the activation of CREB was analyzed at days 1, 3, 5 and 
10 of treatment. Figure 3.8 shows that activation of CREB increases during 
differentiation of control cells, opposite to what is seen in Rin1-overexpressing 
cells: a decrease during the differentiation treatment. Even though these data is 
complex to explain, it is the only difference in signaling that has been found so far 
when Rin1 is overexpressed, so it may help elucidate the exact mechanism by 
which Rin1 inhibit 3T3-L1 preadipocyte differentiation. 
To investigate whether Rin1 has a similar inhibitory effect in other cell 
differentiation systems, a second differentiation system was studied. PC12 cells 
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overexpress the TrkA receptor and respond to NGF differentiating into neuron-
like cells with neurite projections. PC12 cells overexpressing Rin1, Rin2 and Rin3 
were exposed to NGF for ten days and the neurite projections were measured.  
Cells overexpressing the Rin proteins were NGF stimulated and the 
neurite growth quantified 10 days later as described in Materials and Methods. 
Figure 3.9 shows that any of the Rin proteins have a major effect on PC12 
differentiation (percentage of differentiated cells: Control 57.23%, Rin1: 47.62%, 
Rin2 56.5% and Rin3 50.5%). Overexpression of Rin1, Rin2 or Rin3 has no 
effect on the amount of cells that actually commit to differentiation, or in the 
length of the neurite projections. The fact that there seems to be no major effect 
by Rin1 in PC12 differentiation compared to its regulatory role in 3T3-L1 
differentiation, may suggest a receptor and cell specific role of Rin1.  
  
 
  
 71
 
Figure 3.1. Rab5/ Rin1 endogenous expression during 3T3-L1 
differentiation.  
3T3-L1 preadipocytes were induced to differentiate by induction media into 
adipocytes as explained in Material and Methods. Total protein extracts were 
prepared at day 0, 3, 5, and 10. The proteins were subset to 12% SDS PAGE 
electrophoresis, blotted to a nitrocellulose membrane, and probed with antibodies 
specific to Rab5 (A) and Rin1 (B). Relative levels of proteins were determined by 
densitometry as described in Material and Methods. Data represent the 
mean±S.E.M. of three independent experiments. *P<0.05 by Student's t-test. 
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Figure 3.2. Lipid droplet quantification in cells overexpressing Rin proteins 
and Rin1 domains. 
(A) 3T3-L1 preadipocytes overexpressing Rin1, Rin2 and Rin3 proteins were 
differentiated for 10 days as described in Material and Methods. Lipid 
quantification was done and compared to control cells. Results were represented 
as Relative Units (relative lipid contents). The data represent the mean +/- SEM 
of 3 independent experiments.  (B) 3T3-L1 preadipocytes were transfected with 
Rin1 RNAi for different period of times during the differentiation process as 
described in Material and Methods. Lipid quantification was done on day 10 and 
compared to control cells. Results were represented as Relative Units (relative 
lipid contents). The data represent the mean +/- SEM of 3 independent 
experiments. (C) 3T3-L1 preadipocytes overexpressing Rin1 domains were 
differentiated as explained above. Lipid quantification is compared to control and 
cells overexpressing Rin1. Results were represented as Relative Units (relative 
lipid contents).  The data represent the mean +/- SEM of 3 independent 
experiments. *P<0.05 by Student's t-test compared to control cells. 
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Figure 3.3. Different constructs of the domains of Rin1.  
R2 represents the N-terminus of the protein containing the SH2 and PR domains. 
R3 represents the C-terminus of Rin1 containing the Vps9 and RA domains. R4 
represents the Vps9 domain, and R5 the RA domain. 
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Figure 3.4. Adipogenic markers expression in cells overexpressing Rin1.  
3T3-L1 preadipocytes overexpressing Rin1:WT were differentiated for 10 days 
and total protein extracts were prepared as described in Material and Methods. 
Total protein extracts were subset to 10% SDS-PAGE electrophoresis, blotted to 
a nitrocellulose membrane and probed against the following antibodies: (A) 
C/EBPα, (B) PPARγ, (C) P-Erk and T-Erk, (D) P-Akt and T-Akt. Results were 
represented as Relative Units (relative lipid contents). Relative levels of proteins 
were determined by densitometry as described in Material and Methods. Data 
represent the mean±S.E.M. of three independent experiments. *P<0.05 by 
Student's t-test compared to control cells. 
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Figure 3.5. Adipogenic markers expression in cells overexpressing the 
different Rin1 domains.  
3T3-L1 preadipocytes overexpressing Rin1 and the different domains were 
differentiated and total protein extracts were obtained as explained above. The 
nitrocellulose membrane was probed against (A) C/EBPα, (B) PPARγ and (C) P-
Erk. Results were represented as Relative Units (relative lipid contents).  Relative 
levels of proteins were determined by densitometry as described in Material and 
Methods. Data represent the mean±S.E.M. of three independent experiments. 
*P<0.05 by Student's t-test compared to control cells. 
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Figure 3.6. Lipid droplet quantification in cells overexpressing Rin1 
mutants. 
3T3-L1 preadipocytes overexpressing Rin1:WT and the following mutants: R94A, 
Y561F, R94A+Y561F, T580A and R629A, were differentiated for 10 days as 
described in Material and Methods. Lipid quantification was done and compared 
to control cells. Results were represented as Relative Units (relative lipid 
contents). The data represent the mean +/- SEM of 3 independent experiments. 
*P<0.05 by Student's t-test compared to control cells. 
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Figure 3.7. Adipogenic markers expression in cells overexpressing the 
different Rin1 mutants. 
3T3-L1 preadipocytes overexpressing the different Rin1 mutants were 
differentiated for 10 days and total protein extracts were prepared as described in 
Material and Methods. Total protein extracts were subset to 10% SDS-PAGE 
electrophoresis, blotted to a nitrocellulose membrane and probed against the 
following antibodies: (A) C/EBPα, (B) PPARγ, (C) P-Erk and T-Erk. Results were 
represented as Relative Units (relative lipid contents). Relative levels of proteins 
were determined by densitometry as described in Material and Methods. Data 
represent the mean±S.E.M. of three independent experiments. *P<0.05 by 
Student's t-test compared to control cells.  
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Figure 3.8. CREB activation in cells overexpressing Rin1 and control cells.  
3T3-L1 control preadipocytes (A) and cells overexpressing Rin1 (B) were 
induced to differentiate by induction media into adipocytes as explained in 
Material and Methods. Total protein extracts were prepared at day 1, 3, 5, and 
10. The proteins were subset to 12% SDS PAGE electrophoresis, blotted to a 
nitrocellulose membrane, and probed with antibodies specific to T-CREB and P-
CREB. Results were represented as Relative Units (relative lipid contents).  
Relative levels of proteins were determined by densitometry as described in 
Material and Methods. Data represent the mean±S.E.M. of three independent 
experiments. *P<0.05 by Student's t-test. 
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Figure 3.9. Effect of Rin proteins in PC12 differentiation.  
PC12 control cells and overexpressing Rin proteins were stimulated with 
100ng/μl NGF and the neurite growth quantified 10 days later as described in 
Materials and Methods. (A) Percentage of differentiated cells. (B) Average 
branch length. (C) Average number of branches per cell. Pictures were taken at 
day 10 of differentiation for control cells (D), Rin1 (E), Rin2 (F) and Rin3 (G) 
overexpressing cells. *P<0.1 by Student's t-test compared to control cells.
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IV. EXAMINING THE EFFECT OF DEHYDROLEUCODINE IN 
DIFFERENTIATION OF ADIPOSE CELLS.  
Sesquiterpene lactones are a large and structurally diverse group of plant 
second metabolites (Heinrich et al., 1998) with distinctive biological activities, 
including gastric cytoprotector effects (Penissi et al., 1998), anti-migraine 
(Beekman et al., 1997), antiviral and antimicrobial activities (Hayashi et al., 1996; 
Perry and Foster, 1995), anti-tumor (Robles et al., 1995) and neurotoxic effect 
(Cheng et al., 1992).  
Sesquiterpene lactones are also blockers of smooth muscle contractility 
(Hay et al., 1994) aromatase activity (Blanco et al., 1997) and NF-kB activation 
(Hehner et al., 1998; Lyss et al., 1998). Also, it has been found that 
sesquiterpene lactones inhibit the activation of cyclooxygenase and pro-
inflammatory cytokines in macrophages (Hwang et al., 1996). Within the group of 
sesquiterpene lactones, helenalin, which occurs in the aerial portion of Arnica 
Montana L., was also found to block the hormonally induced Sky2 mRNA and Akt 
phosphorylation during early stages of adipocyte differentiation (Auld et al., 
2006). Inhibitory activities have been principally linked to the α-methylene-γ-
lactone function (Heinrich et al., 1998). However, the reduction of the α-
methylene-γ-lactone limited its cytotoxicity effect without affecting the anti-
proliferative and anti-aromatase activity (Blanco et al., 1997). 
Dehydroleucodine (DhL) is a sesquiterpene lactone of the guaianolide 
group, which also contains a α-methylene-γ-lactone ring in its molecule. It was 
first isolated from Lidbeckia pectinata (Bohlmann and Zdero, 1972). The aerial 
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parts of Artemisia douglasiana Besser are also rich in DhL (Giordano et al., 
1990). Chloroform extracts of the air-dried aerial parts of Artemisia douglasiana 
showed significant gastric cytoprotective activity (Giordano et al., 1992). In 
addition, DhL inhibited cell proliferation (Polo et al., 2007) and growth of 
Trypanosome cruzi in culture (Brengio et al., 2000). Recent studies also showed 
the antiproliferative effects of DhL on B16 mouse melanoma cells, without having 
an effect on the normal Melan-A mouse melanocytes (Priestap et al., 2012). 
Furthermore, it has been proved that the exposure of DhL (either transient or 
continuous) to cancer cells inhibits proliferation and promotes apoptosis of 
human cancer cells by the activation of p53 and the DNA damage control 
mechanism, in a dose dependent manner (Costantino et al., 2013). 
To examine the potential role of DhL on the differentiation of 
preadipocytes, cells were incubated with induction media in the presence of 
various concentration of DhL. Figure 4.1A shows that the addition of DhL 
inhibited the lipid content in a dose-dependent manner with an IC50 of 6μM. 
Furthermore, the experimental conditions demonstrate that the addition of DMSO 
(0.2%) exclusively does not hinder 3T3-L1 preadipocytes differentiation.  
To examine the effect of DhL on the viability of 3T3-L1 preadipocytes, 
cells were incubated with induction media in the presence of 8μM DhL for 24hrs 
(Day 1) or throughout the entire 9 days of differentiation (Day 9). Cell viability 
was measured using the MTT colorimetric assay as described in Material and 
Methods section. Figure 4.1A shows that the addition of DhL blocked the 
differentiation of 3T3-L1 preadipocytes whereas cell viability was not affected as 
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compared with DMSO or untreated cells (Figure 4.1B). However, at higher DhL 
concentrations (>10μM), 3T3-L1 preadipocytes detached from the plate, which 
was coupled with a significant reduction in the MTT assay. These results suggest 
that, up to a maximum concentration of 10 μM, DhL has a strong inhibitory 
activity of 3T3-L1 preadipocytes differentiation without significant effect on cell 
viability.  
Adipocyte differentiation can be also monitored by formation of 
intracellular lipid droplets (Rosen and Spiegelman, 2000). As described above, 
3T3-L1 preadipocytes were cultivated and induced to differentiate into adipocytes 
with induction media in the absence or presence of 8μM DhL. At day 9, Oil Red 
O staining showed that an abundant number of lipid droplets suggesting a 
significant lipid accumulation in untreated differentiated cells. However, lipid 
droplets were not observed in untreated non-differentiated cells (compare Figure 
4.2A and B). More importantly, formation of lipid droplets was inhibited by 8μM 
DhL treatment (Figure 4.2C).  These observations were further supported with 
the quantitative measurement of lipid content by determining the absorbance at 
540nm (Figure 4.1A). In addition, DhL treatment significantly inhibited adipogenic 
morphology (i.e., transition from a fibroblast-like shape to an increasingly 
rounded-up appearance with an accumulation of cytoplasmic lipid droplets; 
compare Figure 4.2B and C). 
Given that DhL inhibited differentiation to 3T3-L1 preadipocytes, next it 
was considered whether DhL would inhibit triglyceride accumulation. Cells 
treated with induction medium in the presence of 8µM of DhL accumulated 
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roughly 31±5% of the intracellular triglyceride contained in controls (Figure 4.2D). 
As expected, DMSO-treated cells did not affect the formation of triglyceride 
accumulation as compared with cells incubated with induction media alone. 
Adipogenesis is a highly regulated process requiring coordinated 
expression and activation of key transcriptional factors and signaling molecules 
(Rosen and Spiegelman, 2000). To investigate whether DhL affects the 
expression of PPARγ and C/EBPα, 3T3-L1 preadipocytes were incubated with 
induction media in the absence or presence of 8 μM DhL, and then harvested at 
day 9 for Western blot analysis using anti-PPARγ and C/EBPα antibodies. Figure 
4.3A shows that the addition of DhL clearly attenuated the expression of PPARγ 
and C-EBPα. The effect of DhL on the phosphorylation of Akt1 and Erk1/2 
proteins was also examined. Surprisingly, it was found that the addition of DhL 
did not attenuate phosphorylation of Erk and Akt (Figure 4.3B and C). 
Furthermore, it was tested whether the addition of DhL affected the 
phosphorylation of AMPKα during 3T3-L1 preadipocytes differentiation. The data 
shows that phosphorylation of AMPKα (P-AMPKα) was not inhibited by the 
addition of DhL (Figure 4.3D). In contrast, DhL further enhanced phosphorylation 
of AMPKα (Figure 4.3D). It was also found that the level of total AMPKα 
appeared relatively constant in the presence or absence of DhL. Therefore, these 
results indicated that the level of phosphorylated AMPKα increased in the 
presence of DhL. Interestingly, both PPARγ and C/EBPα are selectively 
expressed during the differentiation of 3T3-L1 preadipocytes. The levels of 
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expression of these transcription factors is undetectable in preadipocytes; 
however, expression increases two days after induction and they are expressed 
five days after the induction of differentiation (Rosen and Spiegelman, 2000). 
Consistent with these observations, it was also observed that the expression of 
PPARγ and C-EBPα was significantly increased with the progression of the 
differentiation of 3T3-L1 preadipocyte (Figure 4.4A and B).  However, DhL 
treatment at the concentration of 8μM significantly blocked the expression of 
PPARγ and C-EBPα (Figure 4.4A and B). In addition, the differentiation of 3T3-
L1 preadipocyte progressed with an increase of the phosphorylation status of 
AMPKα (Figure 4.4C). Treatment with DhL further significantly increased the 
phospho-status of AMPKα, suggesting that DhL also induced the activation of 
AMPKα (Figure 4.3C). Furthermore, the addition of DhL also inhibited, in a 
concentration dependent manner, the expression of FAS (Fatty acid synthase) 
(Figure 4.6). Fatty acid synthase is a key protein in the production of lipids, 
responsible for the synthesis reaction of long-chain fatty acids (Semenkovich, 
1997). On the other hand, AMPK stimulates energy production promoting 
glucose transport and fatty acid oxidation, inhibiting lipogenesis and protein 
synthesis (Daval et al., 2006).   Taken together, these data suggest that DhL 
selectively blocks the expression of FAS, PPARγ and C-EBPα and also 
increases the phosphorylation of AMPKα during the differentiation of 3T3-L1 
preadipocytes. 
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It is also possible that the extent of inhibition is dependent on the timing of 
DhL addition. For this purpose, 8μM DhL was added in discrete periods during 
differentiation (Figure 4.5A). A significant reduction in the differentiation of 3T3-
L1 preadipocytes was observed when compared with DMSO-control cells upon 
early DhL addition, corresponding to days 1 or 3 of treatment (Figure 4.5A and 
B). However, this inhibitory effect was not apparent when DhL was added on day 
5, 7 or at day 8 post-induction. These results indicate that DhL may affect early 
adipocyte gene expression during in vitro differentiation. 
These results clearly show that the addition of DhL inhibited differentiation 
of 3T3-L1 preadipocytes in a dose-dependent manner without a significant effect 
on cell toxicity (Figure 4.1). However, it has been postulated that the non-
saturated α-methylene-γ-lactone function of sesquiterpene lactones produces an 
unspecific toxic effect leading to cell death (Polo et al., 2007). Therefore, it has 
been investigated the effect of DH-DhL, which is a derivative of DhL lacking 
alkylating function, on the differentiation of 3T3-L1 preadipocytes. 
Dehydroleucodine (Figure 4.7, compound 1) can be gently reduced with 
sodium borohydride to give the corresponding 11,13-dihydro derivative (classical 
nomenclature; (Giordano et al., 1990). Analysis of the reaction product (DH-DhL) 
by GC shows that two epimers (Figure 4.7B, compounds 2 and 3) are formed in 
different amounts (Figure 4.7B) due to the generation of a chiral center at C-11 of 
the molecule during reduction. The 11S- epimer (compound 2) is the major 
reaction product (Giordano et al., 1992). It is accompanied by the minor 11R-
epimer (compound 3), and by traces of unreacted DhL (compound 1) (Figure 
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4.7B). In the following these epimers are denoted (11S)DH-DhL and (11R)DH-
DhL, respectively, for simplicity. After separation by preparative HPLC, the 
epimers were obtained in pure form and confirmed by GC analysis (Figure 4.7C 
and D). They were studied, in parallel with DhL, for their effect on the 
differentiation of 3T3-L1 preadipocytes. 
Figure 4.8A shows that the addition of DH-DhL inhibited the differentiation 
of 3T3-L1 preadipocytes. The inhibition was dose-dependent and required a 
higher concentration of DH-DhL to produce a similar inhibitory effect as DhL. 
Thus, it required 10 times the DH-DhL concentration to achieve the same effect 
as DhL (Figure 4.8A). Furthermore, it was also found that 100 μM of DH-DhL did 
not affect cell viability (control cells: 98 ± 2% of viability vs. 80 μM DH-DhL 
treated cells: 97 ± 2% of viability). These results suggest that the reduction of the 
α-methylene-γ-lactone group of the DhL was not required to block the 
differentiation of 3T3- L1 preadipocytes. 
To further investigate the role of these epimers of DH-DhL on the 
differentiation of 3T3-L1 preadipocytes, the two methyl epimers at C-11 produced 
during the in vitro reduction of DhL were separated by preparative HPLC, 
concentrated, confirmed by GC analysis and then their effect on adipogenesis 
was examined. For this, 3T3-L1 pre-adipocytes were incubated with 80 μM of 
either (11S)DH-DhL or (11R)DH-DhL during the entire differentiation process. It 
was found that the addition of (11R)DH-DhL epimer, but not (11S)DH-DhL 
epimer, inhibited the differentiation of 3T3-L1 preadipocytes (Figure 4.8B). These 
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results suggest that (11R)DH-DhL epimer may be responsible in inhibiting 
adipocyte differentiation. 
Several studies have shown that compounds that have the α-methylene-γ-
lactone group can react with nucleophiles, especially cysteine sulfhydryl groups. 
Interestingly, studies indicate that cysteine residues in certain proteins, such as 
NF-kB, may be direct targets of sesquiterpene lactones (Semenkovich, 1997). 
Thus, it is logical to speculate that proteins like Rin1 and Rab5 (Chapters 2 and 
3), whose activities are required for adipogenesis, may be affected by DhL. 
Expression of Rab5 and Rin1, as well as Rab5 activity, showed a strong effect on 
adipogenesis: reducing lipid formation, decreasing the expression of key without 
affecting the major signaling pathways.  To investigate the possible effect of DhL 
on Rin1 and Rab5 function, it was decided to study whether expression of Rin1 
and Rab5 and Rab5 activity were affected by the addition of DhL. Interestingly, 
expression of Rin1 and Rab5 had shown a detrimental effect on adipogenesis, 
which is consistent with the inhibitory effect of the active form of Rab5 in 
adipogenesis (unpublished data Nicole Villaverde, 2009). To this end, 8μM DhL 
was added to cells and the level of expression of Rab5 and Rin1 were examined 
by Western blot analysis. Rab5 activity was determined by the formation of 
enlarged Rab5-positive endosomes in cells overexpressing Rab5:WT and the 
constitutively active mutant Rab5:Q79L (Barbieri et al., 1996). Overexpression of 
Rab5:WT promotes endosomes with an average perimeter of 1.2 -/+ 0.01μm, 
while the overexpression of the constitutively active mutant promotes endosomes 
with an average perimeter of 2.3 -/+ 0.012 μm (Li and Qian, 2002). Figure 4.9A 
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and B shows that DhL did not affect either the expression or activity of Rab5, or 
the expression of Rin1 (Figure 4.10). Taken together, these observations reveal 
that DhL inhibited adipogenesis by a Rin1/Rab5 independent mechanism(s).  
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Figure 4.1. Dehydroleucodine inhibited adipogenesis of 3T3-L1 
preadipocytes without reducing cell viability.  
Dehydroleucodine inhibited adipogenesis of 3T3-L1 preadipocytes without 
reducing cell viability. (A) 3T3-L1 preadipocytes were differentiated into 
adipocytes in the absence or in the presence of various amounts of DhL (0.65 to 
10 μM) as described in Material and Methods. Results were represented as 
relative lipid contents. Data represent the mean±S.E.M. of three independent 
experiments. *P<0.05 by Student's t-test compared to DMSO and only induction 
media-treated cells. (B) Cells were treated with 8 μM DhL for either 24 hrs (day 
1) or for 9 days (day 9). Cell viability was measured using the MTT assay as 
described in Material and Methods. Data represent the mean±S.E.M. of three 
independent experiments. 
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Figure 4.2. Dehydroleucodine blocked the formation of lipid droplet by 
induction media in 3T3-L1 cells.  
Dehydroleucodine blocked the formation of lipid droplet by induction media in 
3T3-L1 cells. Adipocyte differentiation was induced by treating confluent 3T3-L1 
preadipocytes with induction media in the absence or presence of 8 μM DhL. 
Morphological changes of 3T3-L1 preadipocytes were monitored by a 
microscope and photographed after 9 days from the onset of differentiation. (A) 
Vehicle only, (B) cells treated with induction media in the presence of DMSO, or 
(C) in the presence of DhL. (D) Nine days after induction of differentiation, cells 
were lysed for triglyceride and protein assays as described in Material and 
Methods. Vehicle only (line 1), cells treated with induction media alone (line 2), 
cells treated with induction media in the presence of DMSO (line 3), and cells 
treated with induction media in the presence of 8 μM DhL (line 4). Bars=10μm. 
Data represent the mean±S.E.M. of three independent experiments. *P<0.05 by 
Student's t-test compared to DMSO-treated cells and only induction media-
treated cells. 
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Figure 4.3. Dehydroleucodine attenuated the expression of PPARγ during 
3T3-L1 preadipocyte differentiation.  
Dehydroleucodine attenuated the expression of PPARγ during 3T3-L1 
preadipocyte differentiation. 3T3-L1 preadipocytes were induced to differentiate 
by induction media into adipocytes in the absence (inset: −DhL, control) or in the 
presence (inset: +DhL) of 8 μM DhL. Total protein extracts were prepared at day 
9 from each sample. The proteins were subset to 12% SDS-PAGE 
electrophoresis, blotted to a nitrocellulose membrane, and probed with anti-
bodies specific to (A) PPARγ, C-EBPα and tubulin, (B) P-Erk1/2, T-Erk1/2, (C) P-
Akt1, T-Akt1, (D) P-AMPKα and T-AMPKα respectively. Relative levels of 
proteins were determined by densitometry as described in Material and Methods. 
Data represent the mean±S.E.M. of three independent experiments. *P<0.05 by 
Student's t-test compared to DMSO induction media-treated cells (control). 
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Figure 4.4. Dehydroleucodine selectively alters the expression of PPARγ, 
C-EBPα and AMPKα.  
3T3-L1 preadipocytes were induced to differentiate by induction media into 
adipocytes in the absence (insert: -DhL, control) or in the presence (insert: +DhL) 
of 8 μM DhL. Total protein extracts were prepared at day 1, 3, 5, 7 and 9 from 
each sample. The proteins were subset to 12% SDS PAGE electrophoresis, 
blotted to a nitrocellulose membrane, and probed with anti-bodies specific to 
PPARγ (A), C-EBPα (B), AMPKα (C), and tubulin. Relative levels of proteins 
were determined by densitometry as described in Material and Methods. Data 
represent the mean ± S.E.M. of three independent experiments. *P<0.05 by 
Student's t-test compared to DMSO induction media-treated cells (control). 
 93
 
Figure 4.5. Dehydroleucodine blocked adipocyte differentiation in a time-
dependent manner.  
(A) 3T3-L1 preadipocyte cells were treated with 8 μM DhL for the time indicated 
in the schematic representation of the experiment. (B) In each treatment (1–6), 
the accumulation of lipid droplets was measured by the incorporation of Oil Red 
O as de- scribed in Material and Methods. Data represent the mean±S.E.M. of 
three independent experiments. *P<0.05 and **P<0.01 by Student's t-test 
compared to DMSO induction media-treated cells (control). 
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Figure 4.6. Dehydroleucodine alters the expression of FAS. 
3T3-L1 preadipocytes were induced to differentiate by induction media into 
adipocytes in the absence (insert: -DhL, control) or in the presence (insert: +DhL) 
of 8 μM DhL. Total protein extracts were prepared at day 0 (no induction media), 
1, 3, 5, 7 and 9 from each sample. The proteins were subset to 12% SDS PAGE 
electrophoresis, blotted to a nitrocellulose membrane, and probed with anti- FAS 
antibody. Relative levels of proteins were determined by densitometry as 
described in Material and Methods. Data represent the mean ± S.E.M. of three 
independent experiments. *P<0.05 by Student's t-test compared to DMSO 
induction media-treated cells (control). 
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Figure 4.7. GC analysis of dehydroleucodine and 11,13-
dihydrodehydroleucodine epimers.  
(A) DhL isolated from Artemisia douglasiana; (B) mixture DH-DhL epimers as 
obtained by reduction of DhL, (#) denotes small amount of DhL after the 
reduction reaction; (C) DH-DhL epimer S, and, (D) DH-DhL epimer R after 
separation from the mixture. Chemical struc- tures of DhL (compound 1), DH-
DhL epimer 11S (compound 2) and DH-DhL epimer 11R (compound 3) 
(numbering according to classical nomenclature). 
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Figure 4.8. 11,13-Dihydro-dehydroleucodine inhibited 3T3-L1 preadipocyte 
differentiation.  
(A) 3T3-L1 preadipocytes were differentiated into adipocytes in the absence or in 
the presence of either DHL or DH-DhL. Results were represented as relative lipid 
content. Data represent the mean ± S.E.M. of three independent experiments. 
(B) 3T3-L1 preadipocyte cells were incubated with induction media 
supplemented with either DMSO, 80 μM DH-DhL epimer S or 80 μM DH-DhL 
epimer R and the incorporation of Oil Red O was measured by as described in 
Material and Methods. Results were represented as relative lipid content. Data 
represent the mean ± S.E.M. of three independent experiments. *P<0.01 by 
Student's t-test compared to DMSO-treated cells. 
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Figure 4.9. Effect of dehydroleucodine in Rab5 expression and activation.  
(A) To study Rab5 expression, NIH3T3 cells overexpressing GFP-Rab5 
constructs were exposed to 8μM DhL for 6hrs. Then, the cells were lysed and 
total protein extracts were subset to 12% SDS-PAGE electrophoresis, blotted to 
a nitrocellulose membrane, and probed with Rab5 and tubulin antibodies. 
Relative levels of proteins were determined by densitometry as described in 
Material and Methods. Data represent the mean±S.E.M. of three independent 
experiments. To study Rab5 activity NIH3T3 cells overexpressing GFP-Rab5 
constructs were exposed to 8μM DhL for 6hrs. Then, the cells were fixed and the 
perimeter of Rab5-positive endosomes was measured, as described in Material 
and Methods, in cells overexpressing Rab5:WT (B) and Rab5:Q79L (C).  
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Figure 4.10. Effect of dehydroleucodine in Rin1 expression.  
NIH3T3 cells overexpressing Rin1 were exposed to 8μM DhL for 6hrs then lysed 
and total protein extracts were subset to 12% SDS-PAGE electrophoresis, 
blotted to a nitrocellulose membrane, and probed with Rin1 and tubulin 
antibodies. Relative levels of proteins were determined by densitometry as 
described in Material and Methods. Data represent the mean±S.E.M. of three 
independent experiments. 
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V. DISCUSSION 
Tyrosine kinase receptors (RTKs) are expressed in many cell types and 
regulate important biological processes such as cell growth and differentiation, 
among others (Brodeur et al., 2009; Shaham et al., 2008; Wieduwilt and 
Moasser, 2008).  Even though RTKs are the focus of an extensive research area, 
its signaling and regulation have not been completely elucidated. Overactivation 
and/or malfunction of RTKs have been linked to hyperproliferative and other type 
of diseases. Therefore it is important to understand not only the pathway, but 
also the proteins involved in RTK signal transduction and trafficking. It is also 
critical to investigate the molecular mechanism by which these proteins are 
interconnected.  
The scope of this dissertation is a detailed analysis of the function of Rin1, 
a cytosolic protein involved in RTK signaling and internalization. The aim of this 
study is to: 1) determine how key residues of Rin1 are responsible for the 
protein-protein interactions, 2) elucidate how these interactions impact biological 
processes, mainly cell differentiation, and 3) determine the role of small 
molecules on intracellular pathways leading to selective inhibitory effects. 
Misregulation of pathways involved in these biological processes may be a direct 
cause of certain diseases such as cancer, obesity and neurodegenerative 
diseases.  
 The present study shows that Rin1, through several domains, directly 
interacts with EGFR, IR, and NGFR upon ligand stimulation. Rin1-EGFR 
interaction was only observed when Rin1:WT or Rin1:N-terminal domain were 
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utilized, but not with the Rin1:C-terminal domain.  Moreover, NGFR showed a 
similar type of interaction as the one observed for EFGR: through the SH2 
domain. There was no interaction when the C-terminus of Rin1 was utilized. 
However, the IR-Rin1 interaction was not only through the SH2 domain, but also 
with the Vps9 (located at the C-terminal region, suggesting a novel interaction 
with the Vps9 domain and IR.  
The crystal structure of SRC kinase shows the importance of a signature 
motif composed of Phe-Leu-Val-Arg-Glu-Ser (FLVRES) in SH2 domain function 
(Campbell and Jackson, 2003). Mutations in the arginine residue prevent almost 
every interaction with phosphotyrosines (Campbell and Jackson, 2003). In Rin1, 
residue arginine 94 was mutated to alanine creating Rin1:R94A mutant to 
investigate its effect in IR interaction and signaling.  It can be concluded that 
even though this residue, does not affect the protein-protein interaction; it is 
critical for the proper function of the receptor tail. 
Next, it was studied how this RTK-Rin1 interaction affected the 
internalization and signaling processes.  Rin1 affects endocytosis and signal 
transduction via different proteins such as Rab5 and Ras. In the case of Rab5, 
Rin1 acts as a GEF, promoting the exchange from GDP to GTP (Han and 
Colicelli, 1995; Tall et al., 2001). As a consequence, the ligand-receptor complex 
internalization is accelerated, until the complex is separated in the late endosome 
and they both get delivered to the lysosome.  The rate of endocytosis has a 
direct effect on receptor signaling: the faster the internalization, the shorter the 
signaling.  This observation indicates that Rin1 not only regulates membrane 
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receptor signaling by activating Rab5 and accelerating the internalization 
process, but also by decreasing Ras signaling. Thus, when Rin1 is 
overexpressed in the cell upon ligand stimulation, Erk and Akt activities are 
decreased. Directed mutagenesis studies reveal that tyrosine 561 in the Vps9 
domain may be one of the key amino acids for Rin1 function (Galvis et al., 2009). 
It has been shown that point mutation in this residue inhibit Rab5 activation 
(Galvis et al., 2009). In addition, it was found that tyrosine 561 also has an effect 
on the interaction of Rin1 with Ras (Galvis et al., 2009). Even though the 
Rin1:Y561F mutant does not have a direct role in the interaction, it reverses the 
inhibition of Erk and Akt by overexpression of Rin1:WT. Another residue that 
regulates Rin1 function is arginine 629 in the RA domain. It reduces the Ras-
Rin1 interaction, which inhibits both, Erk and Akt activities. These data suggest a 
dual role of Rin1 domains: promoting Rab5 activation and decreasing Ras 
signaling upon ligand stimulation.  
Phosphorylation of EGFR and IR also appears to be affected by the 
overexpression of Rin1, another possible cause of accelerating its internalization, 
decreasing the signal span. Similarly, when Rin2 and Rin3 are overexpressed, 
phosphorylation of the receptor decreases; there is an increase in Rab5 
activation that may help to explain the effect of the Rin family. In contrast, the 
overexpression of the other two members of the Rin family (Rin2 and Rin3) 
seems to have a more cell-specific effect on Ras signaling. Rin2 promotes Erk 
activation upon EGF stimulation, while decreasing it upon insulin stimulation. 
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Consistent with this observation, Rin proteins show a distinctive tissue 
distribution (Gurkan et al., 2005). 
Taken together, Rin proteins have a regulatory role in RTKs internalization 
and cell signaling. Rin1 shows a selective method of interaction with RTKs. This 
study describes a novel mechanism of interaction of Rin1 with IR, which is not 
observed with EGFR or NGFR. It also demonstrates that all domains are 
required for the regulatory role of Rin1 in RTK signaling.  
Next, it was studied the interaction of Rin1 with membrane receptors, and 
its effect on Rab5 and Ras activation affected some biological processes such 
as, proliferation and cell differentiation. It has been shown that Rin1 affected cell 
proliferation as well as thymidine incorporation upon ligand stimulation (Hunker et 
al., 2006b). To determine the importance of Rin1 function in cell differentiation, it 
was decided to investigate two different and well-characterized cell differentiation 
processes: adipogenesis and neurogenesis.  
In the case of adipogenesis, overexpression of Rin1 full-length inhibited 
significantly adipocyte differentiation by decreasing the expression of the key 
transcription factors PPARγ and C/EBPα. Previous studies (unpublished data 
Nicole Villaverde, 2009) showed that Rab5 overexpression inhibits adipogenesis 
in vitro in 3T3-L1 preadipocytes. The inhibition by Rab5 may be, at least in part, 
because its activation promotes receptor degradation terminating its signal. 
Another explanation could be the role of Rab5 on the endosomal localization of 
EEA1 (Simonsen et al., 1998), as well as the nuclear localization of AAPL1 
(Miaczynska et al., 2004). Inhibition in vitro of adipocyte formation by Rin1 
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overexpression confirms and also expands these data, since Rin1 is a Rab5 
GEF. Thus, inactivation of Rab5 must be required for the normal process of 
adipogenesis. Actually, a decrease in adipocytes formation was observed when 
all members of the Rin family were overexpressed; Rin1 showed the greatest 
inhibitory effect.  
Rab5 activation may not be the only factor explaining the inhibitory effect 
of Rin1 in preadipocyte differentiation. Each individual domain of Rin1 seems to 
have the same or similar inhibitory effect, indicating a high level of complexity of 
Rin1 function. Consistent with this observation, individual mutations in selective 
domains of Rin1 partially reversed the inhibitory effect of Rin1:WT. These data 
indicate that all domains of Rin1 and its respective interactions with RTKs, Rab5 
and Ras are necessary for its role in adipogenesis.   
In the case of neurogenesis, several studies have shown that Rab5 
activity inhibits neurite growth, and it has been shown to be related to inactivate 
Rab5 through RabGap5 interaction (Liu et al., 2007).  
Even though each individual RTK signaling pathway has been extensively 
studied, there is no complete understanding of how signal transduction networks 
integrate upon simultaneous stimulus (Volinsky and Kholodenko, 2013). 
Crosstalk between signal transduction pathways occur at different levels: 
receptors, adaptor proteins, GTPases, and transcription factors can be involved 
in more than one pathway at a time resulting in different outcomes (Pawson et 
al., 2001). Some RTKs activate the same signaling pathways with different 
biological outcomes. Upon NGF stimulation, PC12 cells will differentiate, but 
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upon EGF stimulation they will proliferate (Marshall, 1995). The key factor here 
seems to be the phosphorylation span of Erk. NGF-stimulated Erk lasts for hours, 
while the EGF-stimulated is just transiently activated (Heasley and Johnson, 
1992). Rin1 overexpression in PC12 has no effect in neurite growth upon NGF 
stimulation. Thus, until now adipogenesis may be the only differentiation process 
affected by Rin1.   
As indicated in Chapter 1, several small molecules have been implicated 
in different enzymatic activities, for example, RTKs inhibitors (Han et al., 1996). 
As described above, Rin1 and Rab5 have an effect in adipogenesis. In addition, 
other proteins (AMPK, C/EBPα and PPARγ) have been shown to be required in 
different steps of the differentiation processes (Hwang et al., 1997).  
The small molecule DhL showed a selective inhibitory effect in 
adipogenesis (Galvis et al., 2011). It attenuated dramatically the production of 
adipogenic transcriptional factors PPARγ and C-EBPα during adipogenesis 
without altering the activation of Erk and Akt. In addition, it was also found that 
DH-DhL, a derivative of DhL with inactivated α- methylene-γ-lactone function, 
also inhibited the formation of adipocytes. However, it required ten times the DH-
DhL concentration to achieve the same effect as DhL. Based on these 
observations, it is clear that in the adipocyte differentiation model, the α-
methylene-γ-lactone moiety causes a significant decrease of 3T3-L1 
preadipocyte differentiation at lower concentrations without altering cell viability. 
The molecular mechanism by which DhL and DH-DhL inhibit adipogenesis is not 
completely understood, but based on this work it can be concluded that it is 
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independent from the expression and activation of Erk, Akt, Rin1 and Rab5. It is 
important elucidate the direct target(s) of DhL because it can be utilized as a 
potential treatment for obesity and other related diseases.  
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FUTURE WORK 
Further studies need to be carried out in order to understand the role of 
Rin1 in diseased cells at both, cellular and animal levels.  First, it would be 
necessary to study the effect of the Rin1-RTK interaction, thought the SH2 
domain, in receptor degradation and signal attenuation.  Second, study if the role 
of Rin1 through its interaction with Rab5 and Ras is cell/tissue-specific, by using 
other isoforms of the GTPases and examine the effect of these interactions in 
signal transduction and receptor trafficking. Third, to elucidate the molecular 
mechanisms used by Rin1 (and the small molecule DhL) to inhibit adipogenesis. 
All this knowledge may lead to a possible treatment for adipogenesis regulation 
and other diseases related to RTKs signaling and trafficking misregulation. 
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MATERIALS AND METHODS 
Cloning. 
Full length proteins and their domains (cDNAs) were cloned in the following 
vectors according to the technique used: pGEX-4T-1 (for the production of GST 
fusion proteins),t pB42AD and pLexA (for proteins used in the yeast two-hybrid 
system) and pMX-puro (for retrovirus production). 
Point mutations were done using the QuickChange kit by Strategene following 
the manufacturer’s protocol, except for the following mutations that were done by 
Genscript: Rin1:K642A/K662A/L675A and R702A. Oligonucleotide primers for 
cloning and mutagenesis were purchased from Sigma. 
Construction of recombinant retroviruses and stable cell lines expressing 
protein constructs. 
Rin1:WT, Rin1 mutants, Rin2:WT, Rin3:WT and Rab5:WT were sub-cloned into 
EcoRI restriction sites of the pMX-puro vector (Schlessinger, 2002; Zhu et al., 
2001). To make stable cell lines expressing the constructs mentioned above, 
Plat-E packaging cells were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) containing 10% fetal bovine serum (Han and Colicelli, 1995; Wang et 
al., 2002).  
Rin1 depletion in 3T3-L1 cells. 
3T3-L1 cells were transfected with lipofectamin and 100pmol RNAi against Rin1 
either for one time (day 1) every 24hrs or every 48hrs during the differentiation 
process. At day 10, cells were either lysed and Western blotting analysis was 
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performed to confirm Rin1 depletion, or the cells were fixed for lipid content 
quantification. 
Lysate preparation, SDS-PAGE and Western blotting.  
To prepare whole cell lysates, cell monolayers were washed with phosphate 
buffer saline (PBS) and lysed in ice-cold lysis buffer (20mM Tris-HCL, 150mM 
NaCl, 1% Triton-X, 1mM PMSF, 1mM NaF, 1mM sodium orhtovanadate). The 
lysates were clarified by centrifugation, and protein concentrations were 
determined by band intensities on SDS-PAGE gels stained with Coomassie Blue. 
Proteins were resolved by SDS-PAGE and transferred to nitrocellulose 
membranes, blocked and probed with the indicated antibodies. To determine 
relative protein amounts, three representative exposures for each sample were 
quantitated by densitometry analysis. 
GST-fused protein purification. 
pGEX-4T1 constructs (Rin1 full-length, domains and mutants) expressed in BL21 
(DE3) RIPL Escherichia coli were induced with 0.25mM IPTG for three hours. 
Bacterial cells were resuspended in extraction buffer (50mM Tris-HCl, 100mM 
NaCl, 1mM EDTA, 1mM EGTA , 1mM DTT, 1mM PMSF, 1mg/ml lysozyme, 
10ug/ml DNAse, 2ug/ml leupeptin, 2μg/ml aprotinin) and lysed by sonication and 
incubation with 1% Triton X-100. Protein concentrations were determined by 
band intensities on SDS-PAGE gels stain with Coomassie Blue. 
Pull-down assay.  
For in vitro studies, fusion proteins were expressed and purified as in the protein 
purification section. For the GST-Pull-down ten µg of immobilized GST alone and 
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GST-fused protein to glutathione sepharose beads were blocked with 0.1% BSA 
in extraction buffer and then were incubated with different amounts of cell lysate 
for 1h at 4°C in binding buffer. After incubation, the beads were washed three 
times by centrifugation and bound proteins were eluted by the addition of SDS 
sample buffer. Solubilized proteins were separated by SDS-PAGE, and analyzed 
by Western blotting using the appropriate antibody. 
Rab5 activation assay. 
NR6-EGFR and NIH3T3-IR were stimulated as explained in the section of 
“Tyrosine kinase receptor-dependent signaling” below. The activation was done 
using the Rab5 activation assay kit following the manufacturer’s protocol (New 
East Biosciences). Briefly, total cell lysates were incubated with anti-Rab5-GTP 
mouse monoclonal antibody. Then, protein A/G agarose was used to pull down 
the bound Rab5-GTP and it was detected by Western blotting using rabbit anti-
Rab5 antibody.   
Ras activation assay. 
NR6 cells expressing GFP and Rin1:WT  were lysed using lysis buffer 
supplemented with 1 mM PMSF. Lysates (1 ml) were then incubated with 100μl 
glutathione beads containing ~10 μg of GST-RAF at 4ºC while rocking for 1hr. 
After incubation, the beads were washed three times using the lysis buffer. The 
pull-downs were subjected to SDS-PAGE and analyzed by Western Blotting 
using an anti-pan Ras antibody. Relative Units (% of maximum) of proteins were 
determined by densitometry using the ratio of active Ras to total-Ras. 
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Insulin receptor tail phosphorylation. 
Six μl of pure recombinant Insulin receptor tail were diluted in a buffer containing 
10mM MgCl2, 240mM NaCl, 0.05% Triton-X 100, 50mM Tris HCL and 20 mM 
ATP. The reaction was left 30 minutes at room temperature prior to the binding to 
the GST beads explained above. 
Immunoprecipitation assay. 
All immunoprecipitations were performed on cytosol prepared from cells in ice-
cold buffer containing several phosphatase and protein inhibitors as described 
above. After clarification, protein concentrations were measured and samples 
were immunoprecipitated by incubation with the appropriate antibodies followed 
by immobilization on Protein G-Sepharose beads (Amersham Phar-macia 
Biotech). The beads were washed three times with buffer and the bound proteins 
were resuspended in sample buffer and analyzed by SDS–PAGE and Western 
blot with the indicated antibodies. 
Yeast Two-Hybrid assay. 
Two-hybrid LexA DNA binding domain (LexA-BD) and B42 transcription 
activation domain (B42AD) fusion constructs were prepared by ligating cDNAs 
for different proteins or protein fragments into the pLexA (His) and pB42AD (Trp) 
plasmids, respectively (Clontech). Mating and transformation of Yeast-EGY48 
cells were done as described in the MATCHMAKER two-hybrid manual 
(Clontech). The Rin1 constructs were expressed as pB42AD fusion constructs 
whereas Rab5:S34N, HRas:V12, insulin receptor and insulin receptor: kinase 
dead mutants were expressed as pLexA fusion constructs. Yeast-EGY48 co-
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transformants were plated on medium without His (H), Trp (W), Leu (L) or Ura 
(U) (-HWUL) to detect LacZ reporter gene activation due to interaction of 
constructs and on medium without His, Trp, or Ura (-HWU) as a control for 
loading and growth on galactose containing medium. All Rin1, Rab5, Ras and 
insulin receptor constructs were detected by Western blot analysis. For liquid β-
galactosidase (β-gal) assays, yeast was grown on appropriate selective media 
and assayed as described in the yeast β-gal assay manual (Pierce). Results 
were expressed in Units: one unit of β-gal was defined as 1000 xOD420/[time x 
vol xOD660]. 
Tyrosine kinase receptor-depending signaling.  
NR6-EGFR/ NIH3T3-IR/ PC12 cell monolayers were infected with pMX viruses 
(alone or Rin1 proteins) and were serum starved for 3hrs prior to activation with 
100 ng/μl EGF, 100nM insulin or 100nM NGF respectively, for 5 minutes. Cells 
were washed with PBS and lysed (20mM Tris-HCL, 150mM NaCl, 1% Triton-X, 
1mM PMSF, 1mM NaF, 1mM sodium orhtovanadate).  Cell proteins were 
separated by SDS-PAGE, and analyzed by Western blotting using the 
appropriate antibody for different signaling proteins (i.e., phospho and total-Erk, 
Akt, p38 and Junk). Relative levels of the proteins were determined by 
densitometry. 
3T3-L1 preadipocyte differentiation.  
3T3-L1 cells (ATCC) were grown to confluence in DMEM high glucose 
supplemented with 10% fetal bovine serum, 1% penicillin/ streptomycin and 1% 
L-glutamine (growth media) in a humidified atmosphere of 5% CO2 at 37°C. 
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Culture was fed every 48hrs, both for cell growth and differentiation. To trigger 
differentiation cells were exposed to differentiation medium (growth media 
supplemented with 670nM insulin, 65nM dexamethasone and 0.5mM 3-isobutyl-
1-methylxanthine [IBMX]) for the first two days, then fed with post-differentiation 
media (DMEM high glucose supplemented with 5% fetal bovine serum, 1% 
penicillin/streptomycin, 1% L-glutamine and 670nM insulin) for the next seven 
days.  DhL treated cells were exposed to the compound the entire process with 
different concentrations, unless otherwise indicated.  
High-performance liquid chromatography analysis. 
The high-performance liquid chromatography (HPLC) equipment consisted of a 
SpectraSystem SMC1000 solvent delivery system, vacuum membrane degasser, 
P4000 gradient pumps and AS3000 autosampler (Thermo Electro Corporation). 
Column effluent was monitored at 254 nm with Spectra System UV6000LP 
variable wavelength PDA detector and ChromQuest 4.1 software. DhL, (11S)DH-
DhL and (11R)DH-DhL were separated using a C18 YMC column (A-302, 150× 
4.3 mm i.d., S-5 μm, 12 nm; Waters) and the following solvents: A. acetonitrile; 
and B. 0.1% TFA in water. System 1: linear gradient 10% to 100% A in 120 
minutes; flow rate 1 ml/min. Preparative HPLC was performed in the above 
equipment with a XTerra Prep MS C18 OBD column, 15 μm, 19×50 mm (Waters) 
and the solvent system 25% acetonitrile– 75% 0.1% TFA in water (isocratic); flow 
rate 3 ml/min. 
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Gas chromatography (GC)/flame ionization detector (FID) and GC/ mass 
spectrometry (MS) analysis of DhL derivatives. 
GC/FID analyses were performed on a Trace GC Ultra apparatus (Thermo 
Electro Corporation) equipped with a flame ionization detector. The output was 
recorded using a ChromQuest version 4.1 data system. A DB-5MS capillary 
column (0.25 mm i.d. × 30 m; film thickness 0.25 μm; J & W Scientific) was 
employed. The temperature was programmed 105 to 240°C at 3°C/min (linear 
increase) and then the temperature was held at 240°C for 10 minutes. The 
injector temperature was 250°C with a split ratio of 1/20. The detector 
temperature was 270°C. Helium was used as gas carrier at 1 ml/min. DHL, 
(11S)DH-DHL and (11R)DH-DhL were dissolved in ethyl acetate and 2μl of the 
solution was injected. GC/MS determinations were carried out in a Hewlett-
Packard model 6890 instrument coupled to a Q-Mass 910 quadrupole selective 
detector at 70 eV and equipped with a DB-5MS capillary column. Temperature 
program and other conditions were as indicated above. 
DhL derivatives: compound identification. 
Dehydroleucodine {(1S,6S,2R)-9,13-dimethyl-5-methylene-3oxatri- cyclo 
[8.3.0.0b2,6N] trideca-9,12-diene-4,11-dione, IUPAC nomenclature}. DhL 
(compound 1): HPLC (System 1), Rt 27.74 min; GC/MS, Rt 22.72 min; UV/PDA 
λmax 256 nm; MS m/z (rel. int.), 244 (100) M+, 173 (18.2), 145 (19.8), 129 (18.9), 
115 (18.5), 105 (18.3), 91 (62.9), 79 (17.7), 77 (28.4), 65 (21.6), 53 (30.8). 
(1S,2S,5S,6S)-5,9,13-trimethyl-3-oxatricyclo[8.3.0.0b2,6N]trideca-9, 12-diene-
4,11-dione;11,13-dihydro-dehydroleucodine (IUPAC nomenclature), (11S)DH-
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DhL (compound 2): HPLC (System 1), Rt 28.16 min; GC/MS, Rt 21.87; UV/PDA 
λmax 257 nm; MS, m/z (rel. int.): 246 (100) M+, 217 (26.7), 173 (37.6), 172 
(31.2), 145 (26.2), 105 (23.2), 91 (60.7), 77 (26.2), 55 (24.3). (1S,2S,6S,5R)-
5,9,13-trimethyl-3-oxatricyclo[8.3.0.0b2,6N]trideca-9, 12-diene-4,11-dione, 11,13-
dihydro-dehydroleucodine (IUPAC nomenclature), (11R)DH-DhL (compound 3): 
HPLC (System 1), Rt 26.23 min; GC/MS, Rt 22.84; UV/PDA λmax 257 nm; MS, 
m/z (rel. int.): 246 (100) M+, 217 (31.5), 173 (35.5), 172 (33.1), 145 (27.5), 105 
(26.1), 91 (67.1), 77 (29.0), 55 (25.8). 
Effect of DhL in Rin and Rab5 expression and activation. 
NIH3T3 cells overexpressing GFP-Rab5 or Rin1 were exposed to 8μM DhL for 
6hrs. For protein expression, the cells were lysed and total protein extracts were 
subset to 12% SDS-PAGE electrophoresis, blotted to a nitrocellulose membrane, 
and probed with Rab5 or Rin1, and tubulin antibodies. For Rab5 activity, the cells 
were fixed with 2% paraformaldehyde for 20 minutes, and the diameter and 
perimeter of Rab5-positive endosomes were measured using the ImageJ64 
software. 
Adipogenesis quantification.  
On the tenth day of differentiation cells were fixed with 10% formalin in PBS 1hr 
at 4°C.  Oil Red O (Allied Chemical) stock solution (0.6g in 100ml of isopropanol) 
was diluted with 0.6 parts of water, filtered and added to the fixed cells for 15 
minutes at room temperature. Cells were washed with water and analyzed in an 
inverted microscope (photos of lipid droplets were taken).  To quantify the lipid 
droplets, Oil Red O was eluted with 100% isopropanol for 10 minutes at 37°C, 
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collected, and its optical density was measured at 540 nm. Lipid quantification 
was verified by studying the expression levels of adipogenic differentiation 
markers, such as of AMPK, FAS, PPARγ, and C-EBPα by Western blotting as 
explained above.  
Neurogenesis. 
PC12 cells were grown to confluence in DMEM high glucose supplemented with 
5% fetal bovine serum, 10% horse serum, 1% penicillin/streptomycin and 1% L-
glutamine (growth media) in a humidified atmosphere of 5% CO2 at 37°C. Culture 
was fed every 48hrs, both for cell growth and differentiation. To trigger 
neurogenesis cells were exposed to differentiation medium (DMEM, 1% horse 
serum, 1% penicillin/streptomycin and 100ng/ml NGF) during the 10 days 
treatment. Neurite outgrowth was monitored daily and cell processes longer than 
one cell body in diameter was counted as neurites.  
Statistical analysis. 
All experiments presented were repeated a minimum of 3 times. The data 
represent the mean ± SEM. Student’s t test was performed to calculate statistical 
significance. 
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APPENDICES 
Appendix 1 
Primers used to do the point mutations in Rin1. 
1) Rin1: W69E 
  5’ - CTCACCCGGCCCGTGGAGCTGCAGCTGCAAGCCAAC - 3’ 
2) Rin1: A76E 
  5’ - CTGCAGCTGCAAGCCAACGAAGCGGCCGCACTGCAC - 3’ 
3) Rin1: R94A 
  5’ - CCGGGGACGTTCCTCGTGGCGAAATCTAACACCCGCCAG - 3’ 
4) Rin1:Y561F 
  5’ - GAGCTGCTGCTGGCGGCCGAGTTCATGTCGGAGCTGCTGGAGCCCAG 
- 3’ 
5) Rin1:T580A  
  5’ - GAGGGTGGCTACTACCTGGCCAGCCTCTCTGCCAGCCTG - 3’ 
6) Rin1:R629A 
  5’ - CACCTCCTCGCAGTAGCCTATC - 3’ 
7) Rin1: H120L 
  5’ - CCCTCCTTCGTCTCCAGCCTCTACATCCTGGAGAGCCCTGGC - 3’ 
8) Rin1: Y121F 
  5’- CCCTCCTTCGTCTCCAGCCACTTCATCCTGGAGAGCCCTGGC - 3’ 
9) Rin1: Y148F 
  5’ - CCCTCCTTCGTCTCCAGCCACTTCATCCTGGAGAGCCCTGGC - 3’ 
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